{"content":"<li class=\"n-box-item date-title\" data-end=\"1553227199\" data-start=\"1553140800\" data-txt=\"Monday, December 23, 2019\">Thursday, March 21, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3444968\" data-ts=\"1553206979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVAC\" target=\"_blank\">PVAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444968-penn-virginia-denbury-terminate-merger-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Penn Virginia, Denbury terminate merger agreement</a></h4><ul><li>Penn Virginia (NASDAQ:<a href='https://seekingalpha.com/symbol/PVAC' title='Penn Virginia Corporation'>PVAC</a>) and Denbury Resources (NYSE:<a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a>) say they have mutually agreed to <a href=\"https://seekingalpha.com/pr/17452357-penn-virginia-denbury-mutually-agree-terminate-merger-agreement\" target=\"_blank\">terminate their merger deal</a>; DNR <font color=\"green\">+2.5%</font> after-hours while PVAC shares are halted.</li><li>\"Given the caliber and dedication of our team, the high quality of our assets and the strength of our balance sheet, we believe we are well positioned to continue to execute our previously announced two rig development plan, which is expected to be fully funded from cash flow,\" PVAC says.</li><li>Major PVAC shareholders including 10.7% owner Mangrove Partners previously had come out <a href=\"https://seekingalpha.com/news/3412901-mangrove-hikes-penn-virginia-stake-10_7-percent-seeks-end-denbury-deal\" target=\"_blank\">against the merger</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444968\" data-linked=\"Penn Virginia, Denbury terminate merger agreement\" data-tweet=\"$PVAC $DNR - Penn Virginia, Denbury terminate merger agreement https://seekingalpha.com/news/3444968-penn-virginia-denbury-terminate-merger-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3444968-penn-virginia-denbury-terminate-merger-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444962\" data-ts=\"1553204532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444962-ego-dlng-and-zuo-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EGO, AT, DLNG and ZUO among notable after hour movers</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/ORN' title='Orion Group Holdings, Inc.'>ORN</a> <font color=\"green\">+4.8%</font>. <a href='https://seekingalpha.com/symbol/CTRN' title='Citi Trends, Inc.'>CTRN</a> <font color=\"green\">+4.7%</font>. <a href='https://seekingalpha.com/symbol/AT' title='Atlantic Power Corporation'>AT</a> <font color=\"green\">+4.1%</font>. <a href='https://seekingalpha.com/symbol/UBX' title='Unity Biotechnology, Inc.'>UBX</a> <font color=\"green\">+3.5%</font>. <a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color=\"green\">+3.3%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/DLNG' title='Dynagas LNG Partners LP'>DLNG</a> <font color=\"red\">-19%</font>. <a href='https://seekingalpha.com/symbol/ZUO' title='Zuora, Inc.'>ZUO</a> <font color=\"red\">-10.7%</font>. <a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color=\"red\">-6%</font>. <a href='https://seekingalpha.com/symbol/SPNE' title='SeaSpine Holdings Corporation'>SPNE</a> <font color=\"red\">-5.9%</font>. <a href='https://seekingalpha.com/symbol/FRTA' title='Forterra, Inc.'>FRTA</a> <font color=\"red\">-4.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444962\" data-linked=\"EGO, AT, DLNG and ZUO among notable after hour movers\" data-tweet=\"$ORN $CTRN $AT - EGO, AT, DLNG and ZUO among notable after hour movers https://seekingalpha.com/news/3444962-ego-dlng-and-zuo-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3444962-ego-dlng-and-zuo-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444954\" data-ts=\"1553202359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYY\" target=\"_blank\">WYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444954-widepointplus-2_2-double-digit-revenue-growth-trims-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WidePoint +2.2% as double-digit revenue growth trims losses</a></h4><ul>   <li>WidePoint (NYSEMKT:<a href='https://seekingalpha.com/symbol/WYY' title='WidePoint Corporation'>WYY</a>) is <font color=\"green\">2.2% higher</font> after hours following a Q4 earnings report where it nearly broke even on revenues that rose by double digits.</li>    <li>Gross profit rose 25% to $4.5M, mirroring 24% growth in revenues.</li>    <li>Net loss narrowed to $0.4M from the prior year's loss of $0.8M.</li>    <li>EBITDA increased to $1M from $0.3M.</li>    <li>It was a strong finish to a pivotal year, says CEO Jin Kang, \"as we delivered strong financial performance, expanded key customer relationships, as well as secured and implemented several contracts with new customers.\"</li>    <li>\"From a business development standpoint, we continue to execute on our strategy of maintaining solid relationships with our systems integrator partners and customers to upsell and pursue new business.\"</li>    <li>For the full year, it's guiding to revenues of $90M-$93M (vs. one estimate for $93.3M) and EBITDA of $1.9M-$2M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444907-widepoint-beats-revenue\" target=\"_blank\">WidePoint beats on revenue</a> (Mar. 21 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17452186-widepoint-reports-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3444954\" data-linked=\"WidePoint +2.2% as double-digit revenue growth trims losses\" data-tweet=\"$WYY - WidePoint +2.2% as double-digit revenue growth trims losses https://seekingalpha.com/news/3444954-widepointplus-2_2-double-digit-revenue-growth-trims-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3444954-widepointplus-2_2-double-digit-revenue-growth-trims-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444947\" data-ts=\"1553201876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRZN\" target=\"_blank\">HRZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444947-horizon-technology-financeminus-4_1-after-capital-raise-start\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Horizon Technology Finance -4.1% after capital raise start</a></h4><ul><li>Horizon Technology Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/HRZN' title='Horizon Technology Finance'>HRZN</a>) <font color=\"red\">falls 4.1%</font> in after-hours trading after announcing <a href=\"https://seekingalpha.com/pr/17452227-horizon-technology-finance-corporation-announces-offering-common-stock\" target=\"_blank\">a primary offering</a> of 2.0M shares of common stock.</li><li>Expects greenshoe option for up to an additional 300,000 shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3440047-horizon-technology-finance-q4-nii-increases-67-percent\" target=\"_blank\">Horizon Technology Finance Q4 NII increases 67%</a> (March 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444947\" data-linked=\"Horizon Technology Finance -4.1% after capital raise start\" data-tweet=\"$HRZN - Horizon Technology Finance -4.1% after capital raise start https://seekingalpha.com/news/3444947-horizon-technology-financeminus-4_1-after-capital-raise-start?source=tweet\" data-url=\"https://seekingalpha.com/news/3444947-horizon-technology-financeminus-4_1-after-capital-raise-start\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444942\" data-ts=\"1553201114\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTAS\" target=\"_blank\">CTAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444942-cintasminus-3_6-after-q3-revenue-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cintas -3.6% after Q3 revenue guidance cut</a></h4><ul><li>Cintas (NASDAQ:<a href='https://seekingalpha.com/symbol/CTAS' title='Cintas Corporation'>CTAS</a>)<font color=\"red\"> falls 3.6%</font> in after-hours trading after trimming FY2019<a href=\"https://seekingalpha.com/pr/17452222-cintas-corporation-announces-fiscal-2019-third-quarter-results\" target=\"_blank\"> revenue guidance</a> to $6.87B-$6.885B from $6.87B-$6.91B outlook issued in December.</li><li>Compares with consensus estimate of $6.89B.</li><li>Sees FY2019 EPS from continuing operations excluding certain items of  of $7.42-$7.48 vs. December guidance of $7.30-$7.38; consensus of $7.34.</li><li>Fiscal Q3 revenue of $1.68B trails consensus estimate of $1.69B; increased 5.9% from $1.59B a year ago.</li><li>Q3 non-GAAP EPS of $1.84 beats the average analyst estimate of $1.71; compares with $1.37 in the year-ago quarter.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444927-cintas-beats-0_13-misses-revenue\" target=\"_blank\">Cintas beats by $0.13, misses on revenue</a> (March 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444942\" data-linked=\"Cintas -3.6% after Q3 revenue guidance cut\" data-tweet=\"$CTAS - Cintas -3.6% after Q3 revenue guidance cut https://seekingalpha.com/news/3444942-cintasminus-3_6-after-q3-revenue-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3444942-cintasminus-3_6-after-q3-revenue-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444936\" data-ts=\"1553200317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZUO\" target=\"_blank\">ZUO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444936-zuoraminus-9_6-after-mixed-q4-print\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zuora -9.6% after mixed Q4 print</a></h4><ul><li>Zuora (NYSE:<a href='https://seekingalpha.com/symbol/ZUO' title='Zuora, Inc.'>ZUO</a>)<font color=\"red\"> plunges 9.6%</font> after reporting Q4 results that beat on revenue and met on EPS. Subscription revenue grew 35% Y/Y to $46.7M.</li><li>Guidance is provided in ASC 605 and 606.</li><li>ASC 605: Q1 total revenue of $65M to $66M with EPS of -$0.13 to -$0.12. FY20 outlook has total revenue from $293M to $297.5M with EPS from -$0.44 to -$0.40.</li><li>ASC 606: Q1 total revenue of $63.5M to $64.5M with EPS of -$0.14 to -$0.13. FY20 has $289M to $293.5M in revenue and -$0.44 to -$0.40 EPS.</li><li>Consensus: Q1 revenue, $65.36M; Q1 EPS, -$0.12; FY20 revenue, $295.5M; FY20 EPS, -$0.45.</li><li>Earnings call is scheduled for 5 PM with a webcast <a href=\"https://investor.zuora.com/home/default.aspx\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17452196-zuora-reports-record-fourth-quarter-full-year-fiscal-2019-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444915-zuora-eps-line-beats-revenue\" target=\"_blank\">Zuora EPS in-line, beats on revenue</a> (March 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444936\" data-linked=\"Zuora -9.6% after mixed Q4 print\" data-tweet=\"$ZUO - Zuora -9.6% after mixed Q4 print https://seekingalpha.com/news/3444936-zuoraminus-9_6-after-mixed-q4-print?source=tweet\" data-url=\"https://seekingalpha.com/news/3444936-zuoraminus-9_6-after-mixed-q4-print\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444931\" data-ts=\"1553199927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444931-nike-profit-beats-amid-broad-revenue-margin-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike profit beats amid broad revenue, margin gains</a></h4><ul>   <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='NIKE, Inc.'>NKE</a>) topped profit expectations for its fiscal Q3 as it saw growth and higher margins in its core brand and broad geographical strength.</li>    <li>Shares are <font color=\"red\">down 3.5%</font> in early after-hours trade.</li>    <li>Net income came to $1.1B vs. a year-ago loss of $921M, not comparable due to effects from tax reform.</li>    <li>Its core Nike brand saw growth across wholesale and Nike Direct (led there by digital), categories including Sportswear and Jordan and \"continued double-digit growth across footwear and apparel.\"</li>    <li>Converse growth in Asia and digital was more than offset by declines in the U.S. and Europe.</li>    <li>Gross margin rose by 130 basis points to 45.1% amid higher average selling prices, favorable exchange rates and growth in Nike Direct.</li>    <li>Revenue by brand: Nike, $9.1B (up 12% in constant currency); Converse, $463M (down 2% in CC).</li>    <li><a href=\"http://investors.nike.com\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444925-nike-beats-0_03-beats-revenue\" target=\"_blank\">Nike beats by $0.03, beats on revenue</a> (Mar. 21 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17452207-nike-inc-reports-fiscal-2019-third-quarter-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3444931\" data-linked=\"Nike profit beats amid broad revenue, margin gains\" data-tweet=\"$NKE - Nike profit beats amid broad revenue, margin gains https://seekingalpha.com/news/3444931-nike-profit-beats-amid-broad-revenue-margin-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3444931-nike-profit-beats-amid-broad-revenue-margin-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>74&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444897\" data-ts=\"1553198296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444897-sell-siders-say-biogen-may-seek-acquisitions-after-aducanumab-fail\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-siders say Biogen may seek acquisitions after aducanumab fail</a></h4><ul><li>In an interview on CNBC, a Jefferies analyst said that Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"red\">-29.5%</font>) may now be targeting acquisitions after its aducanumab flop. Attractive candidates include Biohaven Pharmaceutical Holding Company (<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a> <font color=\"green\">+8.2%</font>), Neurocrine Biosciences (<a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a> <font color=\"green\">+5.9%</font>), Alder BioPharmaceuticals (<a href='https://seekingalpha.com/symbol/ALDR' title='Alder BioPharmaceuticals, Inc.'>ALDR</a> <font color=\"green\">+6.2%</font>), Sage Therapeutics (<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics, Inc.'>SAGE</a> <font color=\"green\">+3.6%</font>), ACADIA Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a> <font color=\"green\">+3.7%</font>) and GW Pharmaceuticals (<a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a> <font color=\"green\">+3.3%</font>).</li><li>A Stifel analyst agreed, adding that Sarepta Therapeutics (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color=\"green\">+2.1%</font>) could be a target as well.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444897\" data-linked=\"Sell-siders say Biogen may seek acquisitions after aducanumab fail\" data-tweet=\"$BIIB $BHVN $NBIX - Sell-siders say Biogen may seek acquisitions after aducanumab fail https://seekingalpha.com/news/3444897-sell-siders-say-biogen-may-seek-acquisitions-after-aducanumab-fail?source=tweet\" data-url=\"https://seekingalpha.com/news/3444897-sell-siders-say-biogen-may-seek-acquisitions-after-aducanumab-fail\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>67&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444896\" data-ts=\"1553197678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444896-disney-fox-staffing-layoffs-begin-new-fox-workers-get-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney/Fox staffing: Layoffs begin; New Fox workers get stock</a></h4><ul>   <li>High-stakes meetings continue on the Fox lots after the $71B Disney/Fox deal, as CEO Lachlan Murdoch assembled the employees of new Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color=\"green\">+2.8%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color=\"green\">+3.3%</font>) for a town-hall gathering.</li>    <li>He informed those workers that they'd <a href=\"https://variety.com/2019/tv/news/fox-corp-lachlan-murdoch-town-hall-1203169197/\" target=\"_blank\">all receive stock in the new company</a>, <i>Variety</i> notes, with amounts varying depending on tenure ($1,000 worth for those under 10 years, while 20-year-plus veterans would get $3,000 in stock).</li>    <li>\u201cYou\u2019re all owners,\u201d Murdoch said. \u201cEach and every one of you has a voice and we want it to be heard.\u201d</li>    <li>Many took that as a sign that new Fox wouldn't be undergoing the same layoffs expected at the Fox entities taken over by Disney (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color=\"red\">-0.8%</font>), where the <i>Los Angeles Times</i> reported some <a href=\"https://seekingalpha.com/news/3444677-la-times-disney-likely-fire-3000-fox-combination\" target=\"_blank\">3,000-plus job cuts</a> are expected, falling heavily on the Fox side of redundancies.</li>    <li>Those are under way, with <i>Variety</i> noting the cuts already are hitting at the <a href=\"https://variety.com/2019/film/news/layoffs-hit-fox-after-disney-completes-deal-1203169337/\" target=\"_blank\">senior VP, executive VP and president level</a>. Domestic distribution head Chris Aronson was given 60-day notice, and Heather Phillips (executive VP and head of domestic publicity) and Mike Dunn (president of product strategy and consumer business development) also have been let go.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3444896\" data-linked=\"Disney/Fox staffing: Layoffs begin; New Fox workers get stock\" data-tweet=\"$FOX $FOXA $DIS - Disney/Fox staffing: Layoffs begin; New Fox workers get stock https://seekingalpha.com/news/3444896-disney-fox-staffing-layoffs-begin-new-fox-workers-get-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3444896-disney-fox-staffing-layoffs-begin-new-fox-workers-get-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444894\" data-ts=\"1553197046\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARFXF\" target=\"_blank\">ARFXF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444894-biogen-and-eisai-aducanumab-flop-pressures-promis-down-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen and Eisai aducanumab flop pressures ProMIS, down 24%</a></h4><ul><li>Thinly traded nano cap ProMIS Neurosciences (<a href='https://seekingalpha.com/symbol/ARFXF' title='ProMIS Neurosciences, Inc.'>OTCQB:ARFXF</a> <font color=\"red\">-23.5%</font>) is down on almost a 9x surge in volume in apparent sympathy with the drop in Biogen and Eisai after they <a href=\"https://seekingalpha.com/news/3444728-biogen-eisai-bail-aducanumab-alzheimers\" target=\"_blank\">terminated</a> development of Alzheimer's candidate aducanumab, an amyloid beta-targeting monoclonal antibody.</li><li>ProMIS <a href=\"https://seekingalpha.com/pr/17452083-aducanumab-failure-selectivity-toxic-oligomer-essential-treating-root-cause-alzheimers\" target=\"_blank\">says </a>its candidate, <a href=\"https://promisneurosciences.com/wp-content/uploads/2019/02/fact-sheet-updated-02202019-final.pdf\" target=\"_blank\">PMN310</a>, won't suffer the same fate because it selectively binds only to the toxic form of amyloid beta, not the plaque form that aducanumab does or all forms of amyloid beta that Roche's crenezumab does.</li><li>Clinical trials have yet to begin.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444894\" data-linked=\"Biogen and Eisai aducanumab flop pressures ProMIS, down 24%\" data-tweet=\"$ARFXF - Biogen and Eisai aducanumab flop pressures ProMIS, down 24% https://seekingalpha.com/news/3444894-biogen-and-eisai-aducanumab-flop-pressures-promis-down-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3444894-biogen-and-eisai-aducanumab-flop-pressures-promis-down-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444893\" data-ts=\"1553196671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444893-oracleplus-2_5-on-analyst-optimism-after-conference\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle +2.5% on analyst optimism after conference</a></h4><ul><li>Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) <font color=\"green\">gains 2.5%</font> after investor optimism following the Oracle MCX conference.</li><li>Piper Jaffray's Alex Zukin has increased confidence in Oracle management's prediction of FY20 revenue acceleration but is skeptical about the Autonomous Database, saying the \"timeline for success\" is likely years rather than quarters away.</li><li>Cowen's J. Derrick Wood cites enthusiasm from ORCL partners NetSuite and Fusion ERP as evidence of Oracle's continuing strong growth. Wood notes \"incremental positive commentary\" on Autonomous Database products, but echos Zukin in thinking the company can achieve its FY20 goal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444893\" data-linked=\"Oracle +2.5% on analyst optimism after conference\" data-tweet=\"$ORCL - Oracle +2.5% on analyst optimism after conference https://seekingalpha.com/news/3444893-oracleplus-2_5-on-analyst-optimism-after-conference?source=tweet\" data-url=\"https://seekingalpha.com/news/3444893-oracleplus-2_5-on-analyst-optimism-after-conference\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444891\" data-ts=\"1553196315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAK\" target=\"_blank\">BAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444891-lyondell-odebrecht-talks-on-braskem-sale-may-take-time-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lyondell, Odebrecht talks on Braskem sale may take more time - Reuters</a></h4><ul><li>Odebrecht's attempts to sell Braskem (<a href='https://seekingalpha.com/symbol/BAK' title='Braskem S.A.'>BAK</a> <font color='red'>-2.6%</font>) to LyondellBasell (<a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a> <font color='green'>+2.3%</font>) <a href=\"https://www.reuters.com/article/braskem-ma-lyondell/lyondell-odebrecht-talks-on-braskem-slowed-by-sec-filing-naphtha-issues-sources-idUSL1N2160MK\" target=\"_blank\">may take months longer than expected</a> because of issues linked to a delayed U.S. filing and a supply contract, Reuters reports.</li><li>LYB's board has decided that it will not conclude the deal before BAK files its 2017 20-F annual report with the SEC, according to the report; BAK has not yet been able to file the document due to its auditors\u2019 ongoing assessment of its internal controls.</li><li>Another drag on the deal reportedly is the delay in the signing of a long-term supply contract of naphtha, a key raw material for BAK, with Petrobras, whose new CEO Roberto Castello Branco has yet to sign a draft contract left by his predecessor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444891\" data-linked=\"Lyondell, Odebrecht talks on Braskem sale may take more time - Reuters\" data-tweet=\"$BAK $LYB - Lyondell, Odebrecht talks on Braskem sale may take more time - Reuters https://seekingalpha.com/news/3444891-lyondell-odebrecht-talks-on-braskem-sale-may-take-time-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3444891-lyondell-odebrecht-talks-on-braskem-sale-may-take-time-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444888\" data-ts=\"1553194770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLF\" target=\"_blank\">XLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444888-tech-leads-advance-financials-continue-to-lag\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech leads advance, as financials continue to lag</a></h4><ul><li>A bit more than an hour before the close, stocks are at session highs, with the Nasdaq <font color=\"green\">up 1.5%</font>, the S&amp;P 500 <font color=\"green\">1.2%</font>, and the Dow <font color=\"green\">0.95%</font>.</li><li>Not a whole lot happened after the FOMC meeting yesterday, but investors today might have realized the central bank's next move - whenever it comes - is likely to be a rate cut.</li><li>The financial sector continues to lag, with the <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> flat, and big names like JPMorgan (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color='red'>-1.6%</font>), Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-1.2%</font>), PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='The PNC Financial Services Group, Inc.'>PNC</a> <font color='red'>-1.4%</font>), and Wells Fargo (<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Company'>WFC</a> <font color='red'>-1%</font>) solidly in the red. These players borrow short and lend long, but with the yield curve flat, it could crimp profit margins. The 10-year Treasury yield has bounced one basis point today, but at 2.53%, it's still only barely higher than the Fed Funds rate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444888\" data-linked=\"Tech leads advance, as financials continue to lag\" data-tweet=\"$XLF $JPM $BAC - Tech leads advance, as financials continue to lag https://seekingalpha.com/news/3444888-tech-leads-advance-financials-continue-to-lag?source=tweet\" data-url=\"https://seekingalpha.com/news/3444888-tech-leads-advance-financials-continue-to-lag\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444873\" data-ts=\"1553194453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTOO\" target=\"_blank\">TTOO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444873-t2-bio-up-20-on-ge-supply-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T2 Bio up 20% on GE supply deal</a></h4><ul><li>T2 Biosystems (<a href='https://seekingalpha.com/symbol/TTOO' title='T2 Biosystems, Inc.'>TTOO</a> <font color=\"green\">+20.3%</font>) is up on more than double normal volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1492674/000119312519081936/d721459d8k.htm\" target=\"_blank\">agreement </a>with GE Healthcare under which the latter will supply its superparamagnetic particles for use with TTOO's products.</li><li>TTO will serve as a non-exclusive reseller of the particles and has agreed to certain minimum purchase requirements.</li><li>The agreement, cancelable under certain conditions, will be in effect until March 1, 2027. Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444873\" data-linked=\"T2 Bio up 20% on GE supply deal\" data-tweet=\"$TTOO - T2 Bio up 20% on GE supply deal https://seekingalpha.com/news/3444873-t2-bio-up-20-on-ge-supply-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3444873-t2-bio-up-20-on-ge-supply-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444886\" data-ts=\"1553194191\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SM\" target=\"_blank\">SM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444886-sm-energyplus-5-merlin-maximus-development-off-to-successful-start\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SM Energy +5% as Merlin Maximus development off to successful start</a></h4><ul><li>SM Energy (<a href='https://seekingalpha.com/symbol/SM' title='SM Energy Company'>SM</a> <font color='green'>+5%</font>) surges after issuing an <a href=\"https://seekingalpha.com/pr/17451061-sm-energy-provides-first-quarter-update-announces-participation-ipaa-conference\" target=\"_blank\">operational update</a> including reaffirming production guidance despite certain unanticipated events.</li><li>SM says its 25-well Merlin Maximus development is off to a successful start, with all 25 wells drilled and completed as planned and on budget and 24 on production and meeting or exceeding expectations; one well was intentionally shut-in to monitor sub-surface pressure.</li><li>SM also says Permian Basin oil differentials to Cushing  WTI improved significantly YTD, as the company's  pre-hedge net differential improved from ~$9/bbl in  January to $6/bbl in February and is expected to  further improve in March.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444886\" data-linked=\"SM Energy +5% as Merlin Maximus development off to successful start\" data-tweet=\"$SM - SM Energy +5% as Merlin Maximus development off to successful start https://seekingalpha.com/news/3444886-sm-energyplus-5-merlin-maximus-development-off-to-successful-start?source=tweet\" data-url=\"https://seekingalpha.com/news/3444886-sm-energyplus-5-merlin-maximus-development-off-to-successful-start\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444885\" data-ts=\"1553194109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444885-technology-movers-and-shakers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology movers and shakers</a></h4><ul><li><strong>Gainers: </strong>SPI Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a>) <font color=\"green\">+61%</font>. Creative Realities (NASDAQ:<a href='https://seekingalpha.com/symbol/CREX' title='Creative Realities, Inc.'>CREX</a>) <font color=\"green\">+13%</font>. SemiLEDs Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a>) <font color=\"green\">+13%</font>. Superconductor Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a>) <font color=\"green\">+13%</font>. StoneCo (NASDAQ:<a href='https://seekingalpha.com/symbol/STNE' title='StoneCo Ltd.'>STNE</a>) <font color=\"green\">+12%</font>.</li> <li><strong>Losers: </strong>Canadian Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a>) <font color=\"red\">-18%</font>. One Stop Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/OSS' title='One Stop Systems, Inc.'>OSS</a>) <font color=\"red\">-15%</font>. NantHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/NH' title='NantHealth, Inc.'>NH</a>) <font color=\"red\">-10%</font>. JinkoSolar Holding (NYSE:<a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a>) <font color=\"red\">-9%</font>. QAD (NASDAQ:<a href='https://seekingalpha.com/symbol/QADA' title='QAD Inc.'>QADA</a>) <font color=\"red\">-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3444885\" data-linked=\"Technology movers and shakers\" data-tweet=\"$SPI $CREX $LEDS - Technology movers and shakers https://seekingalpha.com/news/3444885-technology-movers-and-shakers?source=tweet\" data-url=\"https://seekingalpha.com/news/3444885-technology-movers-and-shakers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444882\" data-ts=\"1553192725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TME\" target=\"_blank\">TME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444882-tencent-musicplus-4_5-on-target-increase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tencent Music +4.5% on target increase</a></h4><ul><li>HSBC reiterates a Buy rating on Tencent Music (NYSE:<a href='https://seekingalpha.com/symbol/TME' title='Tencent Music Entertainment Group'>TME</a>) and raises the PT from $16 to $20.</li><li>Analyst Binnie Wong sees the company as on track to monetize its 800M+ user base with accelerated growth in paying users for online music.</li><li>Wong sees future growth from expanded music label partnerships, in-house content development, and enrichment of the content offerings.</li><li>TME shares are <font color=\"green\">up 4.5%</font> to $17.39.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444882\" data-linked=\"Tencent Music +4.5% on target increase\" data-tweet=\"$TME - Tencent Music +4.5% on target increase https://seekingalpha.com/news/3444882-tencent-musicplus-4_5-on-target-increase?source=tweet\" data-url=\"https://seekingalpha.com/news/3444882-tencent-musicplus-4_5-on-target-increase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444878\" data-ts=\"1553191253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444878-phunware-and-senestech-among-energy-materials-gainers-amyris-and-bristow-group-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phunware and SenesTech among Energy/Materials gainers; Amyris and Bristow Group among losers</a></h4><ul><li><b>Gainers: </b>Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware Inc.'>PHUN</a>) <font color=\"green\">+47%</font>. SenesTech (NASDAQ:<a href='https://seekingalpha.com/symbol/SNES' title='SenesTech, Inc.'>SNES</a>) <font color=\"green\">+8%</font>. Compass Minerals International (NYSE:<a href='https://seekingalpha.com/symbol/CMP' title='Compass Minerals International, Inc.'>CMP</a>) <font color=\"green\">+8%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy, Inc.'>CHAP</a>) <font color=\"green\">+7%</font>. Valhi (NYSE:<a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"red\">-12%</font>. Bristow Group (NYSE:<a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a>) <font color=\"red\">-9%</font>. Ultrapar Participacoes (NYSE:<a href='https://seekingalpha.com/symbol/UGP' title='Ultrapar Participações S.A.'>UGP</a>) <font color=\"red\">-5%</font>. C&amp;J Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/CJ' title='C&J Energy Services, Inc.'>CJ</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444878\" data-linked=\"Phunware and SenesTech among Energy/Materials gainers; Amyris and Bristow Group among losers\" data-tweet=\"$SNES $CMP $CHAP - Phunware and SenesTech among Energy/Materials gainers; Amyris and Bristow Group among losers https://seekingalpha.com/news/3444878-phunware-and-senestech-among-energy-materials-gainers-amyris-and-bristow-group-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3444878-phunware-and-senestech-among-energy-materials-gainers-amyris-and-bristow-group-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444874\" data-ts=\"1553190693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCHP\" target=\"_blank\">MCHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444874-piper-sees-strong-h2-for-microchip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper sees strong H2 for Microchip</a></h4><ul><li>Piper Jaffray affirms its Overweight rating and Street-high $130 PT after meeting with Microchip Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MCHP' title='Microchip Technology Incorporated'>MCHP</a>) management.</li><li>The firm says the business is \"stabilizing and should experience a strong second half of the year.\"</li><li>Analyst Harsh Kumar is confident the March quarter represents the bottom and sees \"little risk\" to the Q4 outlook.</li><li>There's still a level of uncertainty due to the continuing US-China trade tensions, but a deal could \"significantly boost\" MCHP sales.</li><li>Microchip sales are <font color=\"green\">up 3.3%</font> to $87.09.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444874\" data-linked=\"Piper sees strong H2 for Microchip\" data-tweet=\"$MCHP - Piper sees strong H2 for Microchip https://seekingalpha.com/news/3444874-piper-sees-strong-h2-for-microchip?source=tweet\" data-url=\"https://seekingalpha.com/news/3444874-piper-sees-strong-h2-for-microchip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444865\" data-ts=\"1553188240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSK\" target=\"_blank\">GSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444865-glaxo-up-1-on-new-data-on-antibody-drug-conjugate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glaxo up 1% on new data on antibody-drug conjugate</a></h4><ul><li>GlaxoSmithKline (<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline plc'>GSK</a> <font color=\"green\">+1.1%</font>) is up on below-average volume in response to <a href=\"https://www.gsk.com/en-gb/media/press-releases/gsk-announces-further-positive-data-from-dreamm-1-study-of-anti-bcma-antibody-drug-conjugate/\" target=\"_blank\">updated data</a> from <a href=\"https://clinicaltrials.gov/ct2/show/NCT02064387?intr=GSK2857916&amp;lead=glaxosmithkline&amp;rank=3\" target=\"_blank\">Phase 1</a> clinical trial evaluating GSK2857916 in multiple myeloma. The results were just published in <em>Blood Cancer Journal</em>.</li><li>The overall response rate was 60%, consistent with preliminary results <a href=\"https://seekingalpha.com/news/3317760-glaxos-lead-bcma-adc-candidate-shows-positive-effect-early-stage-study\" target=\"_blank\">announced </a>in December 2017. The complete response rate was 15% over the additional one-year follow-up period. Median progression-free survival &#40;PFS&#41; was 12.0 months, up from 7.9 months reported previously. Median duration of response was 14.3 months.</li><li>No new safety signals were observed.</li><li>GSK2857916 is an antibody-drug conjugate consisting of a humanized anti-BCMA monoclonal antibody linked to a cytotoxic drug called monomethyl auristatin-F. The company in-licensed the linker technology from Seattle Genetics.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444865\" data-linked=\"Glaxo up 1% on new data on antibody-drug conjugate\" data-tweet=\"$GSK - Glaxo up 1% on new data on antibody-drug conjugate https://seekingalpha.com/news/3444865-glaxo-up-1-on-new-data-on-antibody-drug-conjugate?source=tweet\" data-url=\"https://seekingalpha.com/news/3444865-glaxo-up-1-on-new-data-on-antibody-drug-conjugate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444864\" data-ts=\"1553187748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444864-ehealth-and-kingsway-financial-services-only-financial-gainers-whereas-china-bat-group-leads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">eHealth and Kingsway Financial Services only financial gainers whereas; China Bat Group leads losers</a></h4><ul><li><b>Gainers:</b> eHealth, Inc. (NASDAQ:<a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a>) <font color=\"green\">+8%</font>. Kingsway Financial Services (NYSE:<a href='https://seekingalpha.com/symbol/KFS' title='Kingsway Financial Services Inc.'>KFS</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> China Bat Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GLG' title='China Bat Group, Inc.'>GLG</a>) <font color=\"red\">-8%</font>. The Royal Bank of Scotland Group (NYSE:<a href='https://seekingalpha.com/symbol/RBS' title='The Royal Bank of Scotland Group plc'>RBS</a>) <font color=\"red\">-7%</font>. China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance Limited'>XRF</a>) <font color=\"red\">-6%</font>. Banco Santander (NYSE:<a href='https://seekingalpha.com/symbol/BSBR' title='Banco Santander &#40;Brasil&#41; S.A.'>BSBR</a>) <font color=\"red\">-5%</font>. Banco Bradesco (NYSE:<a href='https://seekingalpha.com/symbol/BBD' title='Banco Bradesco S.A.'>BBD</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444864\" data-linked=\"eHealth and Kingsway Financial Services only financial gainers whereas; China Bat Group leads losers\" data-tweet=\"$EHTH $KFS $GLG - eHealth and Kingsway Financial Services only financial gainers whereas; China Bat Group leads losers https://seekingalpha.com/news/3444864-ehealth-and-kingsway-financial-services-only-financial-gainers-whereas-china-bat-group-leads?source=tweet\" data-url=\"https://seekingalpha.com/news/3444864-ehealth-and-kingsway-financial-services-only-financial-gainers-whereas-china-bat-group-leads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444863\" data-ts=\"1553187526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444863-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul><li><strong>Gainers</strong>: SPI Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a>) <font color=\"green\">+69%</font>. Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"green\">+34%</font>. Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware Inc.'>PHUN</a>) <font color=\"green\">+33%</font>. Neurotrope (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRP' title='Neurotrope, Inc.'>NTRP</a>) <font color=\"green\">+17%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"green\">+14%</font>. General Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/GFN' title='General Finance Corporation'>GFN</a>) <font color=\"green\">+14%</font>. Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+13%</font>. ENDRA Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NDRA' title='ENDRA Life Sciences Inc.'>NDRA</a>) <font color=\"green\">+13%</font>. Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"green\">+13%</font>. Fuel Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/FTEK' title='Fuel Tech, Inc.'>FTEK</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers</strong>: Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) <font color=\"red\">-29%</font>. Staffing 360 Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/STAF' title='Staffing 360 Solutions, Inc.'>STAF</a>) <font color=\"red\">-23%</font>. Pyxis Tankers (NASDAQ:<a href='https://seekingalpha.com/symbol/PXS' title='Pyxis Tankers Inc.'>PXS</a>) <font color=\"red\">-20%</font>. Canadian Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a>) <font color=\"red\">-17%</font>. Liquidia Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/LQDA' title='Liquidia Technologies, Inc.'>LQDA</a>) <font color=\"red\">-16%</font>. Guess (NYSE:<a href='https://seekingalpha.com/symbol/GES' title='Guess? Inc.'>GES</a>) <font color=\"red\">-14%</font>. Shineco (NASDAQ:<a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a>) <font color=\"red\">-13%</font>. Corindus Vascular Robotics (NYSEMKT:<a href='https://seekingalpha.com/symbol/CVRS' title='Corindus Vascular Robotics, Inc.'>CVRS</a>) <font color=\"red\">-13%</font>. Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"red\">-12%</font>. PHI (NASDAQ:<a href='https://seekingalpha.com/symbol/PHII' title='PHI, Inc.'>PHII</a>) <font color=\"red\">-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3444863\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SPI $SRNE $NTRP - Midday Gainers / Losers https://seekingalpha.com/news/3444863-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3444863-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444857\" data-ts=\"1553186694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LIFE\" target=\"_blank\">LIFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444857-atyr-pharma-up-15-ahead-of-aacr-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ATyr Pharma up 15% ahead of AACR presentation</a></h4><ul><li>Thinly traded nano cap aTyr Pharma (<a href='https://seekingalpha.com/symbol/LIFE' title='aTyr Pharma, Inc.'>LIFE</a> <font color=\"green\">+14.6%</font>) is up on a 9x surge in volume. This morning, the company <a href=\"https://seekingalpha.com/pr/17451243-atyr-pharma-announces-poster-presentation-2019-american-association-cancer-research-aacr\" target=\"_blank\">announced </a>that results from its pilot study at the University of Nebraska Medical Center will be presented at AACR in Atlanta on April 3.</li><li>The data support the mechanism of action of lead candidate <a href=\"http://www.atyrpharma.com/programs/atyr1923/\" target=\"_blank\">ATYR1923</a>, a fusion protein being developed to treat interstitial lung diseases.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444857\" data-linked=\"ATyr Pharma up 15% ahead of AACR presentation\" data-tweet=\"$LIFE - ATyr Pharma up 15% ahead of AACR presentation https://seekingalpha.com/news/3444857-atyr-pharma-up-15-ahead-of-aacr-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3444857-atyr-pharma-up-15-ahead-of-aacr-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444856\" data-ts=\"1553186499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444856-conagras-q3-beat-shows-progress-via-brand-improvements-promotions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conagra&#39;s Q3 beat shows progress via brand improvements, promotions</a></h4><ul><li>Conagra (<a href='https://seekingalpha.com/symbol/CAG' title='Conagra Brands, Inc.'>CAG</a> <font color=\"green\">+11.2%</font>) shares soar to a YTD high after beating <a href=\"https://seekingalpha.com/news/3444735-conagra-brands-beats-0_02-misses-revenue\" target=\"_blank\">FQ3 earnings</a> expectations after <a href=\"https://www.wsj.com/articles/conagra-reports-strength-in-snacks-frozen-meals-11553169741\" target=\"_blank\">spending on promotions</a> and improvements to its products helped lift sales by 36% Y/Y to $2.71B.</li><li>\"We cannot and will not cut our way to prosperity,\" CAG CEO Sean Connolly said during today's earnings conference call.</li><li>CAG said it spent on promotions at retailers to bolster sales, underscoring a gap between food makers that have invested in improving their brand appeal and others such as Kraft, which said it had cut costs and pulled back on supermarket promotions.</li><li>Q3 \"<a href=\"https://finance.yahoo.com/news/conagra-tops-profit-estimates-price-121107949.html\" target=\"_blank\">results were better than feared</a>,\" Edward Jones analyst Brittany Weissman says, referring to Pinnacle's poor sales during the previous quarter; CAG had blamed poor innovation and quality at Pinnacle for weak Q2 sales, but Q3 sales from Pinnacle fell by mid-single digits.</li><li>\"Right now, it's all about strengthening Pinnacle's big 3: Birds Eye, Duncan Hines and Wish-Bone,\" Connolly said on the earnings call.</li><li>Connolly says CAG is aggressively investing in innovation at Pinnacle and now expects full-year sales of $1.71B-$1.73B, compared with the company's prior guidance of $1.7B-$1.75B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444856\" data-linked=\"Conagra&#39;s Q3 beat shows progress via brand improvements, promotions\" data-tweet=\"$CAG - Conagra&#39;s Q3 beat shows progress via brand improvements, promotions https://seekingalpha.com/news/3444856-conagras-q3-beat-shows-progress-via-brand-improvements-promotions?source=tweet\" data-url=\"https://seekingalpha.com/news/3444856-conagras-q3-beat-shows-progress-via-brand-improvements-promotions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444852\" data-ts=\"1553184920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444852-wiley-in-deal-michigan-state-for-online-programs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wiley in deal with Michigan State for online programs</a></h4><ul>   <li>Wiley Education Services (<a href='https://seekingalpha.com/symbol/JW.A' title='John Wiley & Sons, Inc.'>JW.A</a> <font color=\"green\">+2.7%</font>, <a href='https://seekingalpha.com/symbol/JW.B' title='John Wiley & Sons, Inc.'>JW.B</a> <font color=\"green\">+3.1%</font>) is <a href=\"https://seekingalpha.com/pr/17451881-wiley-education-services-partners-michigan-state-university\" target=\"_blank\">teaming with Michigan State University</a> on existing and new online programs along with associated services.</li>    <li>The initial deal term is for eight years, and it provides for a launch of support for two existing online programs (a master's in Criminal Justice and a masters' in Law Enforcement Intelligence and Analysis) in September 2019. A third offering is set to follow in fall 2020.</li>    <li>Michigan State's criminal justice program is ranked No. 10 by U.S. News and World Report.</li>    <li>The deal includes support as well as a certificate, leveraging market research, marketing, recruitment, and student support services.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3444852\" data-linked=\"Wiley in deal with Michigan State for online programs\" data-tweet=\"$JW.A $JW.B - Wiley in deal with Michigan State for online programs https://seekingalpha.com/news/3444852-wiley-in-deal-michigan-state-for-online-programs?source=tweet\" data-url=\"https://seekingalpha.com/news/3444852-wiley-in-deal-michigan-state-for-online-programs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444848\" data-ts=\"1553184065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444848-conagra-brands-and-energous-among-consumer-gainers-china-automotive-systems-only-loser\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conagra Brands and Energous among consumer gainers; China Automotive Systems only loser</a></h4><ul><li><b>Gainers: </b>Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"green\">+14%</font>. G-III Apparel Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, Ltd.'>GIII</a>) <font color=\"green\">+11%</font>. Arcimoto (NASDAQ:<a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a>) <font color=\"green\">+12%</font>. Conagra Brands (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='Conagra Brands, Inc.'>CAG</a>) <font color=\"green\">+11%</font>. Energous (NASDAQ:<a href='https://seekingalpha.com/symbol/WATT' title='Energous Corporation'>WATT</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444848\" data-linked=\"Conagra Brands and Energous among consumer gainers; China Automotive Systems only loser\" data-tweet=\"$SOLO $GIII $FUV - Conagra Brands and Energous among consumer gainers; China Automotive Systems only loser https://seekingalpha.com/news/3444848-conagra-brands-and-energous-among-consumer-gainers-china-automotive-systems-only-loser?source=tweet\" data-url=\"https://seekingalpha.com/news/3444848-conagra-brands-and-energous-among-consumer-gainers-china-automotive-systems-only-loser\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444841\" data-ts=\"1553181966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRP\" target=\"_blank\">NTRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444841-alzheimers-players-perk-up-on-biogen-eisai-aducanumab-flop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alzheimer&#39;s players perk up on Biogen/Eisai aducanumab flop</a></h4><ul><li>Buying has spiked in three biotechs developing treatments for Alzheimer's disease &#40;AD&#41; in apparent response to Biogen and Eisai's decision to <a href=\"https://seekingalpha.com/news/3444744-biogen-26-percent-aducanumab-flop\" target=\"_blank\">bail on aducanumab</a>.</li><li>Neurotrope (<a href='https://seekingalpha.com/symbol/NTRP' title='Neurotrope, Inc.'>NTRP</a> <font color=\"green\">+5.1%</font>): Enrollment recently <a href=\"https://seekingalpha.com/news/3442346-neurotrope-completes-enrollment-mid-stage-study-bryostatinminus-1-alzheimers\" target=\"_blank\">completed</a> in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03560245?lead=neurotrope&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2 study</a> evaluating Bryostatin-1 in moderate-to-severe AD patients. Topline results should be available this summer.</li><li>Anavex Life Sciences (<a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a> <font color=\"green\">+3.7%</font>): A <a href=\"https://clinicaltrials.gov/ct2/show/NCT03790709?intr=ANAVEX2-73&amp;lead=anavex&amp;phase=1&amp;rank=5\" target=\"_blank\">Phase 2b/3 study</a> evaluating ANAVEX 2-73 in early AD is currently recruiting patients.</li><li>ACADIA Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a> <font color=\"green\">+3.7%</font>): A <a href=\"https://clinicaltrials.gov/ct2/show/NCT03118947?cond=Alzheimer+Disease&amp;lead=acadia&amp;phase=1&amp;rank=2\" target=\"_blank\">Phase 2 open-label extension study</a> is in process evaluating NUPLAZID (pimavanserin) for the treatment of agitation and aggression in AD patients. In November 2017, it <a href=\"https://seekingalpha.com/news/3308609-mid-stage-study-acadias-pimavanserin-hits-primary-endpoint-fails-key-secondaries-shares-7\" target=\"_blank\">reported </a>results from a Phase 2 study in AD psychosis. The trial met the primary endpoint but fell short on key secondary objectives.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444841\" data-linked=\"Alzheimer&#39;s players perk up on Biogen/Eisai aducanumab flop\" data-tweet=\"$NTRP $AVXL $ACAD - Alzheimer&#39;s players perk up on Biogen/Eisai aducanumab flop https://seekingalpha.com/news/3444841-alzheimers-players-perk-up-on-biogen-eisai-aducanumab-flop?source=tweet\" data-url=\"https://seekingalpha.com/news/3444841-alzheimers-players-perk-up-on-biogen-eisai-aducanumab-flop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444839\" data-ts=\"1553181697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LITE\" target=\"_blank\">LITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444839-northland-capital-aggressive-lumentum-buyer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northland Capital &quot;aggressive&quot; Lumentum buyer</a></h4><ul><li>Northland Capital Markets affirms its Outperform rating on Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) as an \"aggressive\" buyer of the stock</li><li>The firm says LITE is trading at a \"significant discount\" despite its \"superior growth, margin and concentration metrics.\"</li><li>Recent results from Lumentum's supply chain show the \"low expectations\" in the valuation and the \"extreme conservatism\" in the firm's estimates, says Northland.</li><li>Price target: $64.</li><li>LITE shares are <font color=\"green\">up 4%</font> to $51.70.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444839\" data-linked=\"Northland Capital &quot;aggressive&quot; Lumentum buyer\" data-tweet=\"$LITE - Northland Capital &quot;aggressive&quot; Lumentum buyer https://seekingalpha.com/news/3444839-northland-capital-aggressive-lumentum-buyer?source=tweet\" data-url=\"https://seekingalpha.com/news/3444839-northland-capital-aggressive-lumentum-buyer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444833\" data-ts=\"1553180741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNRO\" target=\"_blank\">MNRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444833-monroplus-3_4-expands-in-california\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monro +3.4% as it expands in California</a></h4><ul><li>Monro (NASDAQ:<a href='https://seekingalpha.com/symbol/MNRO' title='Monro, Inc.'>MNRO</a>)<font color=\"green\"> advances 3.4%</font> after <a href=\"https://seekingalpha.com/pr/17451173-monro-inc-signs-definitive-agreement-acquire-california-based-certified-tire-and-service\" target=\"_blank\">agreeing to acquire </a> Certified Tire &amp; Service Centers for an undisclosed amount.</li><li>The deal will expand Monro's footprint throughout California and is estimated to add about $45M in annualized sales, representing a sales mix of ~70% service and 30% tires.</li><li>The acquisition includes 40 retail stores in San Francisco, San Diego, and Los Angeles regions and one distribution center in Riverside, CA.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444833\" data-linked=\"Monro +3.4% as it expands in California\" data-tweet=\"$MNRO - Monro +3.4% as it expands in California https://seekingalpha.com/news/3444833-monroplus-3_4-expands-in-california?source=tweet\" data-url=\"https://seekingalpha.com/news/3444833-monroplus-3_4-expands-in-california\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444831\" data-ts=\"1553180559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444831-sorrento-therapeutics-leads-healthcare-gainers-biogen-tops-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sorrento Therapeutics leads healthcare gainers; Biogen tops the losers</a></h4><ul><li><b>Gainers: </b>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"green\">+22%</font>. Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"green\">+18%</font>. Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+15%</font>. ENDRA Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NDRA' title='ENDRA Life Sciences Inc.'>NDRA</a>) <font color=\"green\">+11%</font>. Neos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NEOS' title='Neos Therapeutics, Inc.'>NEOS</a>) <font color=\"green\">+%11</font>.</li><li><b>Losers: </b>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) <font color=\"red\">-28%</font>. Liquidia Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/LQDA' title='Liquidia Technologies, Inc.'>LQDA</a>) <font color=\"red\">-18%</font>. Shineco (NASDAQ:<a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a>) <font color=\"red\">-13%</font>. Motif Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/MTFB' title='Motif Bio plc'>MTFB</a>) <font color=\"red\">-13%</font>. Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444831\" data-linked=\"Sorrento Therapeutics leads healthcare gainers; Biogen tops the losers\" data-tweet=\"$SRNE $SLNO $AXSM - Sorrento Therapeutics leads healthcare gainers; Biogen tops the losers https://seekingalpha.com/news/3444831-sorrento-therapeutics-leads-healthcare-gainers-biogen-tops-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3444831-sorrento-therapeutics-leads-healthcare-gainers-biogen-tops-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444827\" data-ts=\"1553180322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATU\" target=\"_blank\">ATU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444827-actuant-drops-2-on-q2-revenue-miss-mixed-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Actuant drops 2% on Q2 revenue miss; mixed guidance</a></h4><ul><li>Actuant (NYSE:<a href='https://seekingalpha.com/symbol/ATU' title='Actuant Corporation'>ATU</a>) <font color=\"red\">drops 2%</font> after <a href=\"https://seekingalpha.com/pr/17451380-actuant-reports-second-quarter-2019-results\" target=\"_blank\">Q2 results</a> beat EPS estimates but missed on revenue.</li><li>The Q3 guidance has EPS of $0.40 - $0.45 vs. a consensus of $0.37 and revenue of $295 - 305M vs. a consensus of $319.6M.</li><li>ATU reaffirms guidance for FY19, sees EPS of $1.09 - 1.20 vs. a consensus of $1.16 and revenue of $1.15-1.19B vs. a consensus of $1.2B.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444770-actuant-beats-0_02-misses-revenue\" target=\"_blank\">Actuant beats by $0.02, misses on revenue</a> (March 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444827\" data-linked=\"Actuant drops 2% on Q2 revenue miss; mixed guidance\" data-tweet=\"$ATU $EPAC - Actuant drops 2% on Q2 revenue miss; mixed guidance https://seekingalpha.com/news/3444827-actuant-drops-2-on-q2-revenue-miss-mixed-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3444827-actuant-drops-2-on-q2-revenue-miss-mixed-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444824\" data-ts=\"1553179975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESALY\" target=\"_blank\">ESALY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444824-eisai-down-28-on-aducanumab-fail\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eisai down 28% on aducanumab fail</a></h4><ul><li>Ultra-thinly traded Eisai (<a href='https://seekingalpha.com/symbol/ESALY' title='Eisai Co., Ltd.'>OTCPK:ESALY</a> <font color=\"red\">-28%</font>) is down, albeit on only 13,376 shares, in concert with development partner Biogen after the companies terminated development of Alzheimer's candidate aducanumab due to lack of efficacy.</li><li>Eisai closed yesterday in Tokyo at 9,065 yen, down a fraction, although the big move should happen when trading reopens.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444824\" data-linked=\"Eisai down 28% on aducanumab fail\" data-tweet=\"$ESALY - Eisai down 28% on aducanumab fail https://seekingalpha.com/news/3444824-eisai-down-28-on-aducanumab-fail?source=tweet\" data-url=\"https://seekingalpha.com/news/3444824-eisai-down-28-on-aducanumab-fail\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444823\" data-ts=\"1553179748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAVN\" target=\"_blank\">RAVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444823-raven-industries-down-12-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raven Industries down 12% post Q4 results</a></h4><ul><li>Raven Industries (<a href='https://seekingalpha.com/symbol/RAVN' title='Raven Industries, Inc.'>RAVN</a> <font color=\"red\">-12.1%</font>) reported Q4 sales decrease of 8.1% Y/Y to $88M. Sales by segments: Applied Technology $29.23M (-4.1% Y/Y); Engineered Films $49.47M (-11% Y/Y); and Aerostar $9.42M (-4.3% Y/Y).</li><li>Q4 Gross margin<font color=\"red\"> declined by 233 bps</font> to 28.7%.</li><li>Q4 Operating margin <font color=\"red\">declined by 810 bps</font> to 3.8%. Segments operating margins: Applied Technology 22.5% <font color=\"green\">up by 340 bps</font>; Engineered Films 13.1% <font color=\"red\">down by 840 bps</font>; and Aerostar -24.4% <font color=\"red\">down by 2,400 bps</font>.</li><li>EBITDA was $7.25M (-53% Y/Y) and as percentage of sales 8.2% <font color=\"red\">down by 790 bps</font>.</li><li>Segment EBITDA as % of sales: Applied Technology 26% <font color=\"green\">up by 420 bps</font>; Engineered Films 17.6% <font color=\"red\">down by 810 bps</font>; and Aerostar -22% compared to 2.3% a year ago.</li><li>Q4 Expenses: R&amp;D $8.26M (+78.9% Y/Y) and SG&amp;A $13.67M (-0.4% Y/Y).</li><li>Net cash provided by operating activities YTD was $65.95M, compared to $44.96M a year ago.</li><li>Company has Cash and cash equivalents of $65.8M, as of January 31, 2019.</li><li>For first quarter of FY20 Engineered Films Division expects to realize another substantial decline in hurricane recovery film sales versus the prior year comparative period.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444649-raven-reports-q4-results\" target=\"_blank\">Raven reports Q4 results</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444823\" data-linked=\"Raven Industries down 12% post Q4 results\" data-tweet=\"$RAVN - Raven Industries down 12% post Q4 results https://seekingalpha.com/news/3444823-raven-industries-down-12-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3444823-raven-industries-down-12-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444821\" data-ts=\"1553179420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444821-sell-siders-downgrade-biogen-on-aducanumab-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-siders downgrade Biogen on aducanumab exit</a></h4><ul><li>In scant solace to investors, (formerly) bullish sell-side shops have quickly downgraded Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"red\">-28.2%</font>) after it terminated development of Alzheimer's candidate aducanumab.</li><li>Downgrades to Neutral include Mizuho, BofA/Merrill Lynch, Wells Fargo, Atlantic Equities, William Blair, BTIG Research, Goldman Sachs and JPMorgan.</li><li>The iShares Nasdaq Biotechnology ETF (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color=\"red\">-2%</font>) is down on below-average volume due to Biogen's 7.63% weight (third largest behind Amgen and Gilead Sciences). The SPDR S&amp;P Biotech ETF (<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color=\"green\">+0.7%</font>) is in the green.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444821\" data-linked=\"Sell-siders downgrade Biogen on aducanumab exit\" data-tweet=\"$BIIB $IBB $XBI - Sell-siders downgrade Biogen on aducanumab exit https://seekingalpha.com/news/3444821-sell-siders-downgrade-biogen-on-aducanumab-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3444821-sell-siders-downgrade-biogen-on-aducanumab-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444819\" data-ts=\"1553178624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444819-natural-gas-inventory-draw-in-line-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory draw in-line with estimates</a></h4><ul><li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory:</a> <strong>-47 Bcf</strong> vs. -48 Bcf consensus, -204 Bcf last week.</li><li>Futures <font color=\"red\">-0.25%</font> to $2.813.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3444819\" data-linked=\"Natural gas inventory draw in-line with estimates\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory draw in-line with estimates https://seekingalpha.com/news/3444819-natural-gas-inventory-draw-in-line-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3444819-natural-gas-inventory-draw-in-line-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444813\" data-ts=\"1553177744\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITB\" target=\"_blank\">ITB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444813-u-s-mortgage-rates-extend-decline-homebuilders-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. mortgage rates extend decline; homebuilders rise</a></h4><ul><li>The 30-year fixed-rate mortgage <a href=\"https://seekingalpha.com/pr/17451716-mortgage-rates-move-lower\" target=\"_blank\">averages</a> 4.28% for the week ending March 21, down from 4.31% in the previous week and 4.45% from a year ago at this time, according to Freddie Mac's Primary Mortgage Survey.</li><li>\"The combination of improving affordability and more inventory than the last few spring selling seasons should lead to improved home sales demand,\" says Freddie Mac Chief Economist Sam Khater.</li><li>15-year FRM averages 3.71% vs. 3.76 % in the prior week and 3.91% a year ago.</li><li>5-year Treasury-indexed hybrid adjustable-rate mortgage averages 3.84%, unchanged from the previous week, and vs. 3.68% a year ago.</li><li>iShares U.S. Home Construction ETF (NYSE:<a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>) <font color=\"green\">gains 1.2%</font>.</li><li>D.R. Horton (NYSE:<a href='https://seekingalpha.com/symbol/DHI' title='D.R. Horton, Inc.'>DHI</a>) rises 2.0%, Beazer Homes (NYSE:<a href='https://seekingalpha.com/symbol/BZH' title='Beazer Homes USA, Inc.'>BZH</a>) <font color=\"green\">+1.5%</font>, PulteGroup (NYSE:<a href='https://seekingalpha.com/symbol/PHM' title='PulteGroup, Inc.'>PHM</a>)<font color=\"green\"> +1.8%</font>, Hovnanian (NYSE:<a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a>) <font color=\"green\">+4.3%</font>, TRI Pointe Homes (NYSE:<a href='https://seekingalpha.com/symbol/TPH' title='TRI Pointe Group, Inc.'>TPH</a>)<font color=\"green\"> +1.3%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442864-u-s-mortgage-rates-resume-decline\" target=\"_blank\">U.S. mortgage rates resume their decline</a> (March 14)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/MORL' title='UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN'>MORL</a>, <a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a>, <a href='https://seekingalpha.com/symbol/XHB' title='SPDR Homebuilders ETF'>XHB</a>, <a href='https://seekingalpha.com/symbol/ITB' title='iShares U.S. Home Construction ETF'>ITB</a>, <a href='https://seekingalpha.com/symbol/MORT' title='VanEck Vectors Mortgage REIT Income ETF'>MORT</a>, <a href='https://seekingalpha.com/symbol/PKB' title='Invesco Dynamic Building & Construction Portfolio ETF'>PKB</a>, <a href='https://seekingalpha.com/symbol/NAIL' title='Direxion Daily Homebuilders & Supplies Bull 3x Shares ETF'>NAIL</a>, <a href='https://seekingalpha.com/symbol/HOML' title='ETRACS Monthly Reset 2xLeveraged ISE Exclusively Homebuilders ETN'>HOML</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3444813\" data-linked=\"U.S. mortgage rates extend decline; homebuilders rise\" data-tweet=\"$ITB $DHI $BZH - U.S. mortgage rates extend decline; homebuilders rise https://seekingalpha.com/news/3444813-u-s-mortgage-rates-extend-decline-homebuilders-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3444813-u-s-mortgage-rates-extend-decline-homebuilders-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444812\" data-ts=\"1553177557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RYB\" target=\"_blank\">RYB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444812-ryb-educationminus-4_8-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RYB Education -4.8% post Q4 results</a></h4><ul><li>RYB Education (<a href='https://seekingalpha.com/symbol/RYB' title='RYB Education, Inc.'>RYB</a> <font color=\"red\">-4.8%</font>) reports <a href=\"https://seekingalpha.com/pr/17450920-ryb-education-inc-reports-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Q4</a> revenue growth of 15.1% Y/Y to $45M.</li><li>Service revenues increased by 10.7% Y/Y to $38.5M &amp; product revenues increased by 51.9% Y/Y to $6.5M.</li><li>Gross margin <font color=\"red\">declined 162 bps</font> to 17.56%, was primarily due to decreased franchise fee revenue and the increase in staff compensation and operating costs at directly operated kindergartens.</li><li>Adj. EBITDA margin <font color=\"green\">increased 225 bps</font> to 12.22%.</li><li>Number of students enrolled at RYB directly operated kindergartens was 23,627 (+9% Y/Y).</li><li>Net cash outflows from operating activities decreased to $9.5M; due to the pay-out of IPO related disbursements.</li><li>Total cash and equivalents of $104.1M, the decrease in cash balance was primarily driven by acquisition related payments of $41.5M, capex of $11.5M.</li><li><strong>Q1 Outlook:</strong>  Net revenues of $33-34.5M, representing a Y/Y increase of ~15%-20%.</li><li><strong>2019 Outlook: </strong>Net revenues of $180.5-191.5M, representing a Y/Y increase of ~15%-20%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444679-ryb-education-reports-q4-results\" target=\"_blank\">RYB Education reports Q4 results</a> (Mar. 21 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444812\" data-linked=\"RYB Education -4.8% post Q4 results\" data-tweet=\"$RYB - RYB Education -4.8% post Q4 results https://seekingalpha.com/news/3444812-ryb-educationminus-4_8-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3444812-ryb-educationminus-4_8-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444811\" data-ts=\"1553177461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIMO\" target=\"_blank\">SIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444811-silicon-motion-rocky-on-micron-controller-concern\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silicon Motion rocky on Micron controller concern</a></h4><ul><li>Cowen notes that <a href=\"https://seekingalpha.com/article/4250120-micron-technology-inc-mu-ceo-sanjay-mehrotra-q2-2019-results-earnings-call-transcript\" target=\"_blank\">conference call comments</a> seem to show that Micron has taken its NVMe controller in-house, which is a negative development for supplier Silicon Motion (NASDAQ:<a href='https://seekingalpha.com/symbol/SIMO' title='Silicon Motion Technology Corporation'>SIMO</a>).</li><li>Source: <a href=\"https://twitter.com/thenotablecalls?lang=en\" target=\"_blank\">Notable Calls</a>.</li><li>SIMO shares dipped but have since rebounded, <font color=\"green\">up 0.8%</font> to $40.41.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444811\" data-linked=\"Silicon Motion rocky on Micron controller concern\" data-tweet=\"$SIMO - Silicon Motion rocky on Micron controller concern https://seekingalpha.com/news/3444811-silicon-motion-rocky-on-micron-controller-concern?source=tweet\" data-url=\"https://seekingalpha.com/news/3444811-silicon-motion-rocky-on-micron-controller-concern\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444810\" data-ts=\"1553177414\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSL\" target=\"_blank\">GSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444810-global-ship-lease-to-launch-one-for-eight-reverse-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Ship Lease to launch one-for-eight reverse split</a></h4><ul><li>Global Ship Lease (<a href='https://seekingalpha.com/symbol/GSL' title='Global Ship Lease, Inc.'>GSL</a> <font color='red'>-4.4%</font>) announces a <a href=\"https://seekingalpha.com/pr/17450729-global-ship-lease-inc-announces-reverse-stock-split-effective-march-25-2019\" target=\"_blank\">one-for-eight reverse split</a> of its Class A common shares after shareholders approved a reverse split at yesterday's special shareholders meeting.</li><li>The reverse stock split will take effect as of the opening of trading on or about March 25.</li><li>GSL says it made the move to remain in compliance with NYSE continued listing standards; it received notice last November that shares had fallen below the $1.00/share requirement over a  consecutive 30 trading-day period.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444810\" data-linked=\"Global Ship Lease to launch one-for-eight reverse split\" data-tweet=\"$GSL - Global Ship Lease to launch one-for-eight reverse split https://seekingalpha.com/news/3444810-global-ship-lease-to-launch-one-for-eight-reverse-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3444810-global-ship-lease-to-launch-one-for-eight-reverse-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444806\" data-ts=\"1553176247\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PYPL\" target=\"_blank\">PYPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444806-paypalplus-1_0-even-ebay-adds-google-pay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PayPal +1.0% even as eBay adds Google Pay</a></h4><ul><li>PayPal (NASDAQ:<a href='https://seekingalpha.com/symbol/PYPL' title='PayPal Holdings, Inc.'>PYPL</a>),<font color=\"green\"> up 1.0% </font>in early trading, isn't yet hurt by eBay (NASDAQ:<a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a>) <a href=\"https://seekingalpha.com/pr/17451575-ebay-begin-rolling-google-pay-marketplace-platform\" target=\"_blank\">adding Google Pay</a> to its payment options.</li><li>The move was likely priced into PayPal's stock as eBay has been shifting away from PayPal and adding new payment options.</li><li>Google (NASDAQ:<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet Inc.'>GOOG</a>) Pay will be available to Android users starting in early April, joining Apple Pay as the latest payment option on the platform.</li><li>The Google and Apple payment options are currently only accessible when buying from sellers enrolled in eBay's new payments experience, and will be increasingly available to shoppers as the program expands to process more volume in additional geographies, eBay says.</li><li>PayPal was acquired by eBay in 2002 and grew as the payment method for a majority of eBay transactions. PayPal, spun off from eBay in 2015, has been diversifying its business through acquisitions and partnerships.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444089-paypal-partnering-instagram-checkouts\" target=\"_blank\">PayPal partnering with Instagram on Checkouts</a> (March 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444806\" data-linked=\"PayPal +1.0% even as eBay adds Google Pay\" data-tweet=\"$PYPL $EBAY $GOOG - PayPal +1.0% even as eBay adds Google Pay https://seekingalpha.com/news/3444806-paypalplus-1_0-even-ebay-adds-google-pay?source=tweet\" data-url=\"https://seekingalpha.com/news/3444806-paypalplus-1_0-even-ebay-adds-google-pay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444801\" data-ts=\"1553175032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLHR\" target=\"_blank\">MLHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444801-herman-millerplus-3-on-eps-beat-upside-profit-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herman Miller +3% on EPS beat, upside profit guide</a></h4><ul><li>Herman Miller (NASDAQ:<a href='https://seekingalpha.com/symbol/MLHR' title='Herman Miller, Inc.'>MLHR</a>)<font color=\"green\"> </font><font color=\"green\">gains 2.7% </font>pre-market after yesterday's Q3 EPS beat and revenue miss with an upside Q4 EPS forecast from $0.76 to $0.80 (consensus: $0.72) and in-line revenue from $645M to $666M (consensus: $655.97M).</li><li><a href=\"https://seekingalpha.com/pr/17450693-herman-miller-reports-third-quarter-fiscal-2019-results\" target=\"_blank\">Press release</a>.</li><li>Herman Miller's print and the <a href=\"https://seekingalpha.com/news/3444654-williams-sonoma-plus-3-percent-strong-q4-earnings-upside-2019-guidance\" target=\"_blank\">strong Q4 </a>from peer Williams-Sonoma could have furniture/home product stocks moving today. Potential movers include Bed Bath &amp; Beyond (NASDAQ:<a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>), Kimball (NASDAQ:<a href='https://seekingalpha.com/symbol/KBAL' title='Kimball International, Inc.'>KBAL</a>), and Knoll (NYSE:<a href='https://seekingalpha.com/symbol/KNL' title='Knoll, Inc.'>KNL</a>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444591-herman-miller-beats-0_03-misses-revenue\" target=\"_blank\">Herman Miller beats by $0.03, misses on revenue</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444801\" data-linked=\"Herman Miller +3% on EPS beat, upside profit guide\" data-tweet=\"$MLHR $MLHR $BBBY - Herman Miller +3% on EPS beat, upside profit guide https://seekingalpha.com/news/3444801-herman-millerplus-3-on-eps-beat-upside-profit-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3444801-herman-millerplus-3-on-eps-beat-upside-profit-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444800\" data-ts=\"1553174982\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444800-skinnier-fox-rises-new-bulls-in-corner\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skinnier Fox rises with new bulls in corner</a></h4><ul>   <li>Fox Corp. is up premarket (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color=\"green\">+1.4%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color=\"green\">+1.6%</font>) with more bullish initiations coming in for the now-skinnier Fox.</li>    <li>Credit Suisse has started coverage at Outperform with a price target of $46, while Atlantic Equities is Overweight on the stock with a target of $49 (that implies 27% upside).</li><li>Credit Suisse's Douglas Mitchelson expects Fox will log the fastest revenue/EBITDA growth in the media sector in the next few years, even after a slow year for affiliate revenue growth, and calls it a \"free cash flow machine.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444474-bofaml-starts-new-fox-buy\" target=\"_blank\">BofAML starts new Fox at Buy</a> (Mar. 20 2019)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444449-disney-closes-71b-fox-deal-launching-new-era\" target=\"_blank\">Disney closes on $71B Fox deal, launching new era for both</a> (Mar. 20 2019)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3444800\" data-linked=\"Skinnier Fox rises with new bulls in corner\" data-tweet=\"$FOX $FOXA - Skinnier Fox rises with new bulls in corner https://seekingalpha.com/news/3444800-skinnier-fox-rises-new-bulls-in-corner?source=tweet\" data-url=\"https://seekingalpha.com/news/3444800-skinnier-fox-rises-new-bulls-in-corner\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444791\" data-ts=\"1553174466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBMG\" target=\"_blank\">CBMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444791-cellular-biomedicine-down-9-on-pricing-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellular Biomedicine down 9% on pricing stock offering</a></h4><ul> <li>Cellular Biomedicine Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CBMG' title='Cellular Biomedicine Group, Inc.'>CBMG</a>) <a href=\"https://seekingalpha.com/pr/17451485-cellular-biomedicine-group-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices</a> its public offering of 1,029,412 common stock at a price of $17.00/share, for gross proceeds of ~$17.5M.</li><li>Underwriters over-allotment is an additional 154,411 shares.</li><li>Net proceeds will be used for preclinical studies, clinical trials, as well as for working capital and other general corporate purposes.</li><li>Closing date is March 25.</li><li>Shares are down <font color=\"red\">9%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444587-cellular-biomedicine-readies-equity-offering\" target=\"_blank\">Cellular Biomedicine readies equity offering</a> (March 20)</li>                  </ul><div class=\"tiny-share-widget\" data-id=\"3444791\" data-linked=\"Cellular Biomedicine down 9% on pricing stock offering\" data-tweet=\"$CBMG - Cellular Biomedicine down 9% on pricing stock offering https://seekingalpha.com/news/3444791-cellular-biomedicine-down-9-on-pricing-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3444791-cellular-biomedicine-down-9-on-pricing-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444790\" data-ts=\"1553174452\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444790-ino-mbt-and-igc-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">INO, MBT and IGC among premarket gainers</a></h4><ul><li>SPI Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a>) <font color=\"green\">+115%</font> on <a href=\"https://seekingalpha.com/pr/17451000-spi-energy-co-ltd-completes-acquisition-1_998-megawatts-solar-pv-projects-greece\" target=\"_blank\">completing</a> its previously announced second-stage acquisition of 100% of the equity interest of HELIOHRISI S.A.</li><li>One Stop Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/OSS' title='One Stop Systems, Inc.'>OSS</a>) <font color=\"green\">+35%</font> on <a href=\"https://seekingalpha.com/pr/17451267-oss-introduces-world-s-first-pcie-gen-4-backplane-nvidia-gpu-technology-conference\" target=\"_blank\">introducing</a> the world\u2019s first PCIe Gen 4 backplane.</li><li>Superconductor Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/news/3444704-superconductor-technologies-beats-0_87\" target=\"_blank\">Q4 earnings</a>.</li><li>Conformis (NASDAQ:<a href='https://seekingalpha.com/symbol/CFMS' title='Conformis, Inc.'>CFMS</a>) <font color=\"green\">+14%</font>.</li><li>Ritter Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals, Inc.'>RTTR</a>) <font color=\"green\">+9%</font>.</li><li>G-III Apparel (NASDAQ:<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, Ltd.'>GIII</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/news/3444720-g-iii-apparel-beats-0_12-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Conagra Brands (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='Conagra Brands, Inc.'>CAG</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3444735-conagra-brands-beats-0_02-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Mechel PAO (NYSE:<a href='https://seekingalpha.com/symbol/MTL' title='Mechel PAO'>MTL</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3444708-mechel-pao-reports-fy-results\" target=\"_blank\">FY earnings</a>.</li><li>Inovio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a>) <font color=\"green\">+7%</font> as <a href=\"https://seekingalpha.com/pr/17451359-inovios-ebola-vaccine-delivered-intradermally-demonstrates-100-percent-immunogenicity\" target=\"_blank\">Ebola vaccine</a>, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses.</li><li>OPKO Health (NASDAQ:<a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a>) <font color=\"green\">+7%</font> on positive OPK88003 <a href=\"https://seekingalpha.com/news/3444765-opko-7-percent-premarket-positive-opk88003-data\" target=\"_blank\">data</a>.</li><li>PolarityTE (NASDAQ:<a href='https://seekingalpha.com/symbol/PTE' title='PolarityTE, Inc.'>PTE</a>) <font color=\"green\">+7%</font> on positive <a href=\"https://seekingalpha.com/news/3444659-polarityte-plus-4_3-percent-evercore-sees-potential-double\" target=\"_blank\">upgrade</a>.</li><li>Public Joint-Stock Company Mobile TeleSystems (NYSE:<a href='https://seekingalpha.com/symbol/MBT' title='Public Joint-Stock Company Mobile TeleSystems'>MBT</a>) <font color=\"green\">+6%</font>.</li><li>India Globalization Capital (NYSEMKT:<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc.'>IGC</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444790\" data-linked=\"INO, MBT and IGC among premarket gainers\" data-tweet=\"$SPI $OSS $SCON - INO, MBT and IGC among premarket gainers https://seekingalpha.com/news/3444790-ino-mbt-and-igc-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3444790-ino-mbt-and-igc-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444787\" data-ts=\"1553174138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444787-biib-and-csiq-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BIIB and CSIQ among premarket losers</a></h4><ul><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) <font color=\"red\">-27%</font> after <a href=\"https://seekingalpha.com/news/3444744-biogen-26-percent-aducanumab-flop\" target=\"_blank\">aducanumab</a> flop.</li><li>Pyxis Tankers (NASDAQ:<a href='https://seekingalpha.com/symbol/PXS' title='Pyxis Tankers Inc.'>PXS</a>) <font color=\"red\">-26%</font> on <a href=\"https://seekingalpha.com/news/3444738-pyxis-tankers-misses-0_09-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Staffing 360 Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/STAF' title='Staffing 360 Solutions, Inc.'>STAF</a>) <font color=\"red\">-19%</font> on <a href=\"https://seekingalpha.com/news/3444636-staffing-360-solutions-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Liquidia Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/LQDA' title='Liquidia Technologies, Inc.'>LQDA</a>) <font color=\"red\">-17%</font> on <a href=\"https://seekingalpha.com/news/3444784-liquidia-tech-17-percent-pricing-stock-offering-11_50\" target=\"_blank\">pricing</a> stock offering.</li><li>Guess (NYSE:<a href='https://seekingalpha.com/symbol/GES' title='Guess? Inc.'>GES</a>) <font color=\"red\">-14%</font> on <a href=\"https://seekingalpha.com/news/3444607-guess-misses-0_05-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Shineco (NASDAQ:<a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a>) <font color=\"red\">-13%</font>.</li><li>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"red\">-10%</font>.</li><li>Canadian Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3444700-canadian-solar-beats-0_45-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Cellular Biomedicine Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CBMG' title='Cellular Biomedicine Group, Inc.'>CBMG</a>) <font color=\"red\">-8% </font>on <a href=\"https://seekingalpha.com/news/3444587-cellular-biomedicine-readies-equity-offering\" target=\"_blank\">initiating</a> common stock offering.</li><li>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"red\">-8%</font>.</li><li>Estre Ambiental (NASDAQ:<a href='https://seekingalpha.com/symbol/ESTR' title='Estre Ambiental, Inc.'>ESTR</a>) <font color=\"red\">-8%</font>.</li><li>The Royal Bank of Scotland Group (NYSE:<a href='https://seekingalpha.com/symbol/RBS' title='The Royal Bank of Scotland Group plc'>RBS</a>) <font color=\"red\">-6%</font>.</li><li>Intelsat S.A. (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) <font color=\"red\">-7%</font>.</li><li>frontdoor (NASDAQ:<a href='https://seekingalpha.com/symbol/FTDR' title='frontdoor, inc.'>FTDR</a>) <font color=\"red\">-5%</font> on <a href=\"https://seekingalpha.com/news/3444673-frontdoor-prices-secondary-offering-remaining-shares-held-servicemaster\" target=\"_blank\">pricing</a> secondary offering.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3444787\" data-linked=\"BIIB and CSIQ among premarket losers\" data-tweet=\"$BIIB $PXS $STAF - BIIB and CSIQ among premarket losers https://seekingalpha.com/news/3444787-biib-and-csiq-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3444787-biib-and-csiq-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444785\" data-ts=\"1553174054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANET\" target=\"_blank\">ANET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444785-goldman-adds-arista-to-conviction-buy-list\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman adds Arista to Conviction Buy list</a></h4><ul><li>Goldman Sachs adds Arista Networks (NYSE:<a href='https://seekingalpha.com/symbol/ANET' title='Arista Networks, Inc.'>ANET</a>) to its Conviction Buy list and sees significant upside potential in the expansion into campus switching.</li><li>The firm notes that ANET has one of the highest EPS growth profiles in its coverage universe.</li><li>Goldman expects Arista to deliver 23%+ revenue growth in 2020 and 2021 with the campus expansion representing 4% and 6% of the total, respectively.</li><li>The firm raises its ANET price target from $300 to $360.</li><li>Arista shares are <font color=\"green\">up 1.9%</font> pre-market to $304.</li><li>Post updated to correct the price target change.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444785\" data-linked=\"Goldman adds Arista to Conviction Buy list\" data-tweet=\"$ANET - Goldman adds Arista to Conviction Buy list https://seekingalpha.com/news/3444785-goldman-adds-arista-to-conviction-buy-list?source=tweet\" data-url=\"https://seekingalpha.com/news/3444785-goldman-adds-arista-to-conviction-buy-list\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444784\" data-ts=\"1553173529\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LQDA\" target=\"_blank\">LQDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444784-liquidia-tech-down-17-on-pricing-stock-offering-11_50\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Liquidia Tech down 17% on pricing stock offering at $11.50</a></h4><ul> <li>Liquidia Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/LQDA' title='Liquidia Technologies, Inc.'>LQDA</a>) <a href=\"https://seekingalpha.com/pr/17451206-liquidia-technologies-announces-pricing-offering-common-stock\" target=\"_blank\">prices</a> its public offering of 3M common stock at a price of $11.50, for total gross proceeds of $34.5M.</li><li>Underwriters over-allotment is an additional 450,000 shares.</li><li>Closing date is March 25.</li><li>Shares are down <font color=\"red\">17%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443840-liquidia-tech-files-3m-share-stock-offering\" target=\"_blank\">Liquidia Tech files for 3M-share stock offering</a>(March 18)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3444784\" data-linked=\"Liquidia Tech down 17% on pricing stock offering at $11.50\" data-tweet=\"$LQDA - Liquidia Tech down 17% on pricing stock offering at $11.50 https://seekingalpha.com/news/3444784-liquidia-tech-down-17-on-pricing-stock-offering-11_50?source=tweet\" data-url=\"https://seekingalpha.com/news/3444784-liquidia-tech-down-17-on-pricing-stock-offering-11_50\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444783\" data-ts=\"1553173509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444783-micron-cut-to-sell-on-continued-pressure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron cut to Sell on continued pressure</a></h4><ul><li>Citi downgrades Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) from Neutral to Sell on the belief that shares and estimates will remain under pressure even after the earnings beat due to the DRAM crash.</li><li>The firm notes that Micron guided weak due to the memory crash and cut capex, which are the appropriate steps.</li><li>Micron shares are <font color=\"green\">up 3.6%</font> pre-market to $41.55.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444601-micron-plus-2_2-percent-q2-beats-capex-cut\" target=\"_blank\">Micron +2.2% after Q2 beats, capex cut</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444783\" data-linked=\"Micron cut to Sell on continued pressure\" data-tweet=\"$MU - Micron cut to Sell on continued pressure https://seekingalpha.com/news/3444783-micron-cut-to-sell-on-continued-pressure?source=tweet\" data-url=\"https://seekingalpha.com/news/3444783-micron-cut-to-sell-on-continued-pressure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>136&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444780\" data-ts=\"1553173330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSIQ\" target=\"_blank\">CSIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444780-canadian-solarminus-9-after-warning-of-low-negative-2019-profit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Solar -9% after warning of &#39;low or negative&#39; 2019 profit</a></h4><ul><li>Canadian Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a>) <font color=\"red\">-9.4%</font> pre-market after reporting better than expected <a href=\"https://seekingalpha.com/news/3444700-canadian-solar-beats-0_45-beats-revenue\" target=\"_blank\">Q4 earnings</a> but <a href=\"https://www.pv-tech.org/news/canadian-solars-project-business-to-stall-in-2019-hit-on-profits\" target=\"_blank\">warning</a> that its net profit in 2019 will be lower than the previous year.</li><li>\"While we have a strong 2.9 GWp late-stage solar project pipeline, due to the typical project development cycle, we expect to realize sales for the majority of these late-stage projects in 2020 or later. This will likely create a temporary pullback in 2019 compared to 2018,\" CSIQ says.</li><li>The company also expects lower profit in 2019 from its module manufacturing business, partly due to higher costs caused by the appreciation of the Chinese currency vs. the U.S. dollar and euro in recent months.</li><li>As a result, CSIQ sees Q1 revenues of $450M-$480M, compared to $901M in Q4 2018 and $1.42B in the year-ago quarter, while net profit will come in \"low or negative,\" despite module shipments of 1.3-1.4 GW, in line with 1.37 GW shipped in the prior-year period.</li><li>For FY 2019, CSIQ forecasts revenues of $3.5B-$3.8B vs. $3.74B analyst consensus estimate with total module shipments of 7.4-7.8 GW, reflecting the impact of an expected lower module ASP and lower revenue from solar project sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444780\" data-linked=\"Canadian Solar -9% after warning of &#39;low or negative&#39; 2019 profit\" data-tweet=\"$CSIQ - Canadian Solar -9% after warning of &#39;low or negative&#39; 2019 profit https://seekingalpha.com/news/3444780-canadian-solarminus-9-after-warning-of-low-negative-2019-profit?source=tweet\" data-url=\"https://seekingalpha.com/news/3444780-canadian-solarminus-9-after-warning-of-low-negative-2019-profit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444765\" data-ts=\"1553172427\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPK\" target=\"_blank\">OPK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444765-opko-up-7-premarket-on-positive-opk88003-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OPKO up 7% premarket on positive OPK88003 data</a></h4><ul><li>OPKO Health (NASDAQ:<a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a>) is up <font color=\"green\">7%</font> premarket on increased volume on the heels of positive <a href=\"https://seekingalpha.com/pr/17451261-opko-announces-positive-topline-results-phase-2-diabetes-obesity-trial\" target=\"_blank\">topline results</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03406377?intr=opk88003&amp;lead=opko&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2</a> dose-escalation study evaluating OPK88003, a weekly injectable oxyntomodulin compound with dual glucagon-like-peptide 1 (GLP-1) and glucagon agonist activity, in adult type 2 diabetics with inadequate blood sugar control with metformin and/or diet and exercise.</li><li>The study assessed the effects of a dose-escalation regimen of OPK88003 on HbA1c, weight loss and safety over 30 weeks in 113 subjects.</li><li>Patients in the treatment group experienced an average 1.30% drop in HbA1c compared to a 0.09% reduction in the control arm (p&lt;0.0001). 50% of subjects receiving OPK88003 achieved HbA1c levels of 6.5% or lower compared to 13.8% for the control group (a level below 7.0% is considered a good target for diabetics).</li><li>Patients in the treatment arm experienced average weight loss of 4.4 kg at week 30 compared to an average loss of 1.8 kg for the placebo group (p=0.01). About 38% of treated patients lost at least 5% of their baseline weight versus 13% for placebo (p=0.008).</li><li>The average decrease in triglycerides from baseline favored OPK88003 (-31.2 mg/dL compared to -11.6 mg/dL) but the separation from placebo was not statistically significant (p=0.44).</li><li>No new safety signals were observed. The most frequent treatment-related adverse events, mostly mild, were nausea, vomiting and diarrhea.</li><li>The data will be presented at the American Diabetes Association meeting in San Francisco, June 7-11.</li><li>Phase 3 studies are next up.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444765\" data-linked=\"OPKO up 7% premarket on positive OPK88003 data\" data-tweet=\"$OPK - OPKO up 7% premarket on positive OPK88003 data https://seekingalpha.com/news/3444765-opko-up-7-premarket-on-positive-opk88003-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3444765-opko-up-7-premarket-on-positive-opk88003-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444771\" data-ts=\"1553171980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIEGY\" target=\"_blank\">SIEGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444771-siemens-moves-higher-on-report-of-potential-turbine-unit-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Siemens moves higher on report of potential turbine unit merger</a></h4><ul><li>Siemens (<a href='https://seekingalpha.com/symbol/SIEGY' title='Siemens Aktiengesellschaft'>OTCPK:SIEGY</a>) rises as much as 2.5% in German trade following a <em>Manager</em> magazine report that the company is <a href=\"https://www.reuters.com/article/us-siemens-m-a-stocks/siemens-shares-rally-on-turbine-unit-merger-report-idUSKCN1R2117\" target=\"_blank\">exploring a merger of its struggling turbine unit</a> with an Asian partner.</li><li>Siemens CEO Joe Kaeser has relaunched negotiations with Japan\u2019s Mitsubishi Heavy Industries and its gas turbine unit Mitsubishi Hitachi Power Systems, according to the report, which also says Siemens could enter a joint venture with the Japanese companies for building large gas and steam generators while keeping the profitable service business.</li><li>Siemens\u2019 Power and Gas business has been a sore spot for the company, with a 19% drop in revenue during the financial year which ran to Sept. 30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444771\" data-linked=\"Siemens moves higher on report of potential turbine unit merger\" data-tweet=\"$SIEGY - Siemens moves higher on report of potential turbine unit merger https://seekingalpha.com/news/3444771-siemens-moves-higher-on-report-of-potential-turbine-unit-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3444771-siemens-moves-higher-on-report-of-potential-turbine-unit-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444764\" data-ts=\"1553171613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVCN\" target=\"_blank\">NVCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444764-neovasc-prevails-in-tiara-patent-dispute-in-germany-shares-up-20-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neovasc prevails in Tiara patent dispute in Germany, shares up 20%  premarket</a></h4><ul> <li>Neovasc (NASDAQ:<a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a>) <a href=\"https://seekingalpha.com/pr/17451198-neovasc-wins-german-court-appeal-announces-german-courts-decision-dismiss-cardiaqs-claim-co\" target=\"_blank\">announces</a> that a German court has dismissed a patent infringement case brought by Edwards Lifesciences' CardiAQ LLC.</li><li>The German court found that CardiAQ had not contributed to the invention of the Tiara and found Neovasc to be the rightful inventor and owner of all rights to the European patent application.</li><li>Shares are up <font color=\"green\">20%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3424621-neovasc-28-percent-premarket-settlement-patent-infringement-action-edwards\" target=\"_blank\">Neovasc up 28% premarket on settlement of patent infringement action by Edwards</a> (Jan. 22)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3444764\" data-linked=\"Neovasc prevails in Tiara patent dispute in Germany, shares up 20%  premarket\" data-tweet=\"$NVCN - Neovasc prevails in Tiara patent dispute in Germany, shares up 20% premarket https://seekingalpha.com/news/3444764-neovasc-prevails-in-tiara-patent-dispute-in-germany-shares-up-20-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3444764-neovasc-prevails-in-tiara-patent-dispute-in-germany-shares-up-20-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444760\" data-ts=\"1553170614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444760-canopy-growth-buys-u-s-hemp-company-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canopy Growth buys U.S. hemp company; shares up 1% premarket</a></h4><ul><li>Aimed at accelerating its entry into the U.S. hemp market, Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) <a href=\"https://seekingalpha.com/pr/17451236-canopy-growth-acquires-hemp-company-accelerate-expansion-united-states\" target=\"_blank\">acquires </a>AgriNextUSA for an undisclosed sum.</li><li>AgriNextUSA plans to develop hemp industrial parks in the U.S., the first in New York State.</li><li>Shares are up <font color=\"green\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444760\" data-linked=\"Canopy Growth buys U.S. hemp company; shares up 1% premarket\" data-tweet=\"$CGC - Canopy Growth buys U.S. hemp company; shares up 1% premarket https://seekingalpha.com/news/3444760-canopy-growth-buys-u-s-hemp-company-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3444760-canopy-growth-buys-u-s-hemp-company-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444756\" data-ts=\"1553170202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CZR\" target=\"_blank\">CZR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444756-fertitta-may-partner-icahn-in-second-bid-for-caesars-ny-post\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fertitta may partner with Icahn in second bid for Caesars - NY Post</a></h4><ul><li>Caesars Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment Corporation'>CZR</a>) <font color=\"green\">+2.4%</font> pre-market after the <em>New York Post</em> reports Tilman Fertitta is <a href=\"https://nypost.com/2019/03/20/carl-icahn-may-partner-up-with-tilman-fertitta-for-caesars-bid/\" target=\"_blank\">gearing up to make a second run</a> at the company, possibly with help from controlling shareholder Carl Icahn.</li><li>CZR rebuffed Fertitta's merger offer in November, sending the Golden Nugget Casino  owner on a quest for cash partners to shore up his bid; what has changed since then is the number of the shares Fertitta would need to purchase thanks to Icahn's desire for a  strategic partner combined with his newfound sway over the company, according to the report.</li><li>Icahn has been buying up CZR shares for  months and now is said to own a 28.5% stake including swaps, and the <em>Post</em> says he would not sell his shares if he feels he is partnering with a strategic  buyer who will whip the place into shape, and thus drive up the sagging  stock; as a result, any buyer approved by Icahn, including Fertitta, has  to buy only 71.5% of the company, making the deal far more affordable.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444756\" data-linked=\"Fertitta may partner with Icahn in second bid for Caesars - NY Post\" data-tweet=\"$CZR - Fertitta may partner with Icahn in second bid for Caesars - NY Post https://seekingalpha.com/news/3444756-fertitta-may-partner-icahn-in-second-bid-for-caesars-ny-post?source=tweet\" data-url=\"https://seekingalpha.com/news/3444756-fertitta-may-partner-icahn-in-second-bid-for-caesars-ny-post\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444753\" data-ts=\"1553169783\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLF\" target=\"_blank\">XLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444753-banks-margins-come-under-pressure-from-dovish-fed-baird\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks&#39; margins come under pressure from dovish Fed: Baird</a></h4><ul><li>Banks' net interest margins face pressure from a more-dovish Fed, leading to lending spread compression. deposit re-mixing, and potential for yield-curve inversion, Baird analyst David George writes in a note.</li><li>Sees analysts cutting 2019, 2020 NIM estimates as Fed rate hikes are subtracted from consensus.</li><li>He recommends that investors be disciplined in their exposure to banks considering \"bank valuations are tempting\"  relative to the broader market.</li><li>Financial Select Sector SPDR ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>) <font color=\"red\">slips 0.7%</font> in premarket trading.</li><li>Individual names also sliding premarket: Bank of America (NYSE:<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>) <font color=\"red\">-0.9%</font>, JPMorgan Chase (NYSE:<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a>) <font color=\"red\">-0.9%</font>, Citigroup (NYSE:<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>) <font color=\"red\">-0.9%</font>, Wells Fargo (NYSE:<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Company'>WFC</a>) <font color=\"red\">-0.8%</font>, Goldman Sachs (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='The Goldman Sachs Group, Inc.'>GS</a>) <font color=\"red\">-0.5%</font>, Morgan Stanley (NYSE:<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>)<font color=\"red\"> -0.7%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444573-financial-sector-goes-south-post-fomc\" target=\"_blank\">Financial sector goes south post-FOMC</a> (March 20)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3444753\" data-linked=\"Banks&#39; margins come under pressure from dovish Fed: Baird\" data-tweet=\"$XLF $BAC $JPM - Banks&#39; margins come under pressure from dovish Fed: Baird https://seekingalpha.com/news/3444753-banks-margins-come-under-pressure-from-dovish-fed-baird?source=tweet\" data-url=\"https://seekingalpha.com/news/3444753-banks-margins-come-under-pressure-from-dovish-fed-baird\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444750\" data-ts=\"1553169589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPTH\" target=\"_blank\">BPTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444750-bio-path-down-13-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bio-Path down 13% premarket</a></h4><ul><li>Nano cap Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) is the latest example of the wild ride that tiny biotechs can deliver. Shares rocketed from $2.60 on February 28 to a high of $73.52 on March 7 on <a href=\"https://seekingalpha.com/news/3440262-bio-path-54-percent-premarket-positive-prexigebersen-data\" target=\"_blank\">positive Phase 2 data</a> on prexigebersen in AML.</li><li>Shares are currently exchanging hands at $18.75 premarket, down <font color=\"red\">13%</font> from yesterday's close of $21.50 and down <font color=\"red\">74% </font>from the intraday high on March 7.</li><li>The company just completed an $18.5M capital raise via the sale of 712,910 common shares at $25.95, representing a <font color=\"red\">28% </font>loss thus far for investors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444750\" data-linked=\"Bio-Path down 13% premarket\" data-tweet=\"$BPTH - Bio-Path down 13% premarket https://seekingalpha.com/news/3444750-bio-path-down-13-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3444750-bio-path-down-13-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444749\" data-ts=\"1553169533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444749-conagra-foodsplus-4-on-bottom-line-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ConAgra Foods +4% on bottom-line beat</a></h4><ul><li>ConAgra Foods (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='Conagra Brands, Inc.'>CAG</a>) reports net sales growth of 36% in <a href=\"https://seekingalpha.com/pr/17202793-conagra-brands-completes-third-year-transformation-strong-end-fiscal-2018\" sasource=\"qp_sum_news_38\" target=\"_blank\">Q3</a>, driven primarily by the Pinnacle Foods acquisition.</li><li>Organic net sales grew 1.9%.</li><li>Segment net sales: Grocery &amp; Snacks: $863M (+2.9%); Refrigerated &amp; Frozen: $711M (+3.3%); International: $198M (+11.4%); Foodservice: $223M (-8.7%); Pinnacle: $712M.</li><li>Adjusted gross margin rate fell 110 bps to 28.9%.</li><li><b>FY2019 Guidance</b>: Organic net sales: ~+1%; Adjusted gross margin rate: below range of 29.3% to 29.7%; Adjusted operating margincrate: above range of 14.9% to 15.2%; Adjusted net interest expense: $390M to $395M; Average diluted shares: ~446M; Adjusted diluted EPS: $2.03 to $2.08; Tax rate: 24% to 25%; Synergies: $20M; Pinnacle net sales: $1.71B to $1.73B.</li><li>CAG <font color=\"green\">+3.93%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444735-conagra-brands-beats-0_02-misses-revenue\" target=\"_blank\">ConAgra Brands beats by $0.02, misses on revenue</a> (March 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444749\" data-linked=\"ConAgra Foods +4% on bottom-line beat\" data-tweet=\"$CAG - ConAgra Foods +4% on bottom-line beat https://seekingalpha.com/news/3444749-conagra-foodsplus-4-on-bottom-line-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3444749-conagra-foodsplus-4-on-bottom-line-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444747\" data-ts=\"1553168980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QRVO\" target=\"_blank\">QRVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444747-goldman-boosts-qorvo-on-stabilizing-smartphones\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman boosts Qorvo on stabilizing smartphones</a></h4><ul><li>Goldman Sachs maintains a Neutral rating on Qorvo (NASDAQ:<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc.'>QRVO</a>) but raises the target from $66 to $79 citing a \"compelling valuation\" and \"early signs of smartphone unit stabilization.\"</li><li>The firm sees near-term upside in China offsetting the \"marginal weakness\" of Apple, where the iPhone cuts seem to have abated or at least become more marginal in size.</li><li>Goldman sees the opportunity for Qorvo to expand margins with cost cuts and restructuring.</li><li>QRVO is <font color=\"green\">up 2.5%</font> pre-market to $70.83.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444747\" data-linked=\"Goldman boosts Qorvo on stabilizing smartphones\" data-tweet=\"$QRVO - Goldman boosts Qorvo on stabilizing smartphones https://seekingalpha.com/news/3444747-goldman-boosts-qorvo-on-stabilizing-smartphones?source=tweet\" data-url=\"https://seekingalpha.com/news/3444747-goldman-boosts-qorvo-on-stabilizing-smartphones\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444745\" data-ts=\"1553168572\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444745-futures-point-to-lower-open\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Futures point to lower open</a></h4><ul><li>One day after stocks couldn't hold gains following the FOMC's dovishness, they're poised to open to the downside.</li><li>S&amp;P 500, DJIA, and Nasdaq 100 futures are all <font color=\"red\">down about 0.4%</font>.</li><li>Asia was up modestly overnight, and Europe is slightly in the red at midday.</li><li>There are still Q4 earnings reports rolling in, but in individual stock news, it's all about Biogen - <font color=\"red\">down about 25%</font> after <a href=\"https://seekingalpha.com/news/3444728-biogen-eisai-bail-aducanumab-alzheimers\" target=\"_blank\">pulling its trial</a> for Alzheimer's drug aducanumab.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444745\" data-linked=\"Futures point to lower open\" data-tweet=\"Futures point to lower open https://seekingalpha.com/news/3444745-futures-point-to-lower-open?source=tweet\" data-url=\"https://seekingalpha.com/news/3444745-futures-point-to-lower-open\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444744\" data-ts=\"1553168456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444744-biogen-down-26-after-aducanumab-flop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen down 26% after aducanumab flop</a></h4><ul><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) is down <font color=\"red\">26%</font> premarket after it and development partner Eisai (<a href='https://seekingalpha.com/symbol/ESALY' title='Eisai Co., Ltd.'>OTCPK:ESALY</a>) <a href=\"https://seekingalpha.com/news/3444728-biogen-eisai-bail-aducanumab-alzheimers\" target=\"_blank\">announced </a>that they terminated two late-stage studies of Alzheimer's candidate aducanumab due to lack of efficacy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444744\" data-linked=\"Biogen down 26% after aducanumab flop\" data-tweet=\"$BIIB $ESALY - Biogen down 26% after aducanumab flop https://seekingalpha.com/news/3444744-biogen-down-26-after-aducanumab-flop?source=tweet\" data-url=\"https://seekingalpha.com/news/3444744-biogen-down-26-after-aducanumab-flop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>83&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444742\" data-ts=\"1553168392\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIII\" target=\"_blank\">GIII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444742-g-iii-apparelplus-8-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">G-III Apparel +8% post Q4 results</a></h4><ul><li>G-III Apparel (NASDAQ:<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, Ltd.'>GIII</a>) reports net sales rose 7.3% in <a href=\"https://seekingalpha.com/pr/17451088-g-iii-apparel-group-ltd-announces-fourth-quarter-full-year-fiscal-2019-results\" target=\"_blank\">Q4</a>.</li><li>Gross margin rate dropped 240 bps to 33.8%.</li><li>SG&amp;A expense rate improved 440 bps to 26.3%.</li><li>Operating margin rate advanced 280 bps to 5.8%.</li><li>Inventory up 4.2% to $576.38M.</li><li><b>Q1 Guidance</b>: Net sales: ~$650M; Net income: $7M to $12M; Diluted EPS: $0.13 to $0.23; Adjusted EPS: $0.15 to $0.25.</li><li><b>FY2020 Guidance</b>: Net sales: ~$3.28B; D&amp;A: $40M; Interest and financing charges, net: $46M; Income tax expense: $59M to $60M; Net income: $162M to $167M; Diluted EPS: $3.18 to $3.28; Adjusted net income: $167M to $172M; Adjusted EPS: $3.25 to $3.35; Adjusted EBITDA: $307M to $313M.</li><li>GIII <font color=\"green\">+8.08%</font> premarket</li><li>Previously: <a href=\"https://seekingalpha.com/news/3444720-g-iii-apparel-beats-0_12-misses-revenue\" target=\"_blank\">G-III Apparel beats by $0.12, misses on revenue</a> (March 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3444742\" data-linked=\"G-III Apparel +8% post Q4 results\" data-tweet=\"$GIII - G-III Apparel +8% post Q4 results https://seekingalpha.com/news/3444742-g-iii-apparelplus-8-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3444742-g-iii-apparelplus-8-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444740\" data-ts=\"1553168211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CFMS\" target=\"_blank\">CFMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444740-conformis-poised-to-add-to-rally-up-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conformis poised to add to rally, up 8% premarket</a></h4><ul><li>Micro cap Conformis (NASDAQ:<a href='https://seekingalpha.com/symbol/CFMS' title='Conformis, Inc.'>CFMS</a>) is up <font color=\"green\">8%</font> premarket modestly higher volume. Shares have rallied <font color=\"green\">124%</font> since closing at $1.15 on March 11.</li><li>On March 13, it <a href=\"https://seekingalpha.com/pr/17442657-3d-designed-conformis-hip-system-announced-2019-aaos-conference\" target=\"_blank\">announced </a>that its 3D-designed hip system would be featured at the American Academy of Orthopedic Surgeons conference in Las Vegas that week.</li><li>Over 200 surgeries have have been completed since July 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444740\" data-linked=\"Conformis poised to add to rally, up 8% premarket\" data-tweet=\"$CFMS - Conformis poised to add to rally, up 8% premarket https://seekingalpha.com/news/3444740-conformis-poised-to-add-to-rally-up-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3444740-conformis-poised-to-add-to-rally-up-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444739\" data-ts=\"1553168038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444739-citi-boosts-apple-on-buyback-dividend-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi boosts Apple on buyback, dividend potential</a></h4><ul><li>Citi raises its Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) price target from $170 to $220 on expectations of a $100B buyback boost and a dividend increase next month.</li><li>Analyst Jim Suva expects FCF of $60B to $65B annually.</li><li>Suva on short interest: \u201cMany growth investors have a negative view on the shares with short interest as a % of free float the highest it has ever been over the past 2 years.\"</li><li>Rating reiterated at Buy.</li><li>Apple shares are <font color=\"green\">up 0.5%</font> pre-market to $189.17.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444739\" data-linked=\"Citi boosts Apple on buyback, dividend potential\" data-tweet=\"$AAPL - Citi boosts Apple on buyback, dividend potential https://seekingalpha.com/news/3444739-citi-boosts-apple-on-buyback-dividend-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3444739-citi-boosts-apple-on-buyback-dividend-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444736\" data-ts=\"1553167809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIII\" target=\"_blank\">GIII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444736-g-iii-pops-8-q4-earnings-top-estimates-sees-bright-2020-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">G-III pops 8% as Q4 earnings top estimates, sees bright 2020 outlook</a></h4><ul><li>G-III Apparel (NASDAQ:<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, Ltd.'>GIII</a>) <font color=\"green\">+8.1%</font> pre-market after easily beating <a href=\"https://seekingalpha.com/news/3444720-g-iii-apparel-beats-0_12-misses-revenue\" target=\"_blank\">Q4 earnings</a> expectations and guiding FY 2020 earnings and revenues above  analyst consensus.</li><li>GIII says Q4 results capped a record year for net sales, adjusted EBITDA, net income and net income per share for the company and its DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger and Karl Lagerfeld brands.</li><li>The company issues mixed guidance for Q1, seeing EPS of $0.15-$0.25 vs. $0.25 analyst consensus estimate on revenues of ~$650M vs. $647M consensus.</li><li>But GIII offers upside guidance for FY 2020, seeing EPS of  $3.25-$3.35 vs. $3.07 consensus on revenues of ~$3.28B vs. $3.26B consensus.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444736\" data-linked=\"G-III pops 8% as Q4 earnings top estimates, sees bright 2020 outlook\" data-tweet=\"$GIII - G-III pops 8% as Q4 earnings top estimates, sees bright 2020 outlook https://seekingalpha.com/news/3444736-g-iii-pops-8-q4-earnings-top-estimates-sees-bright-2020-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3444736-g-iii-pops-8-q4-earnings-top-estimates-sees-bright-2020-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444735\" data-ts=\"1553167801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444735-conagra-brands-beats-0_02-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ConAgra Brands beats by $0.02, misses on revenue</a></h4><ul><li>ConAgra Brands (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='Conagra Brands, Inc.'>CAG</a>): Q3 Non-GAAP EPS of $0.51 <span style=\"color:green\">beats by $0.02</span>; GAAP EPS of $0.50.</li><li>Revenue of $2.71B (+36.2% Y/Y) <font color=\"red\">misses by $40M</font>.</li><li>Shares <font color=\"green\">+2.62%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17451162-conagra-brands-reports-third-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3444735\" data-linked=\"ConAgra Brands beats by $0.02, misses on revenue\" data-tweet=\"$CAG - ConAgra Brands beats by $0.02, misses on revenue https://seekingalpha.com/news/3444735-conagra-brands-beats-0_02-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3444735-conagra-brands-beats-0_02-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444733\" data-ts=\"1553167563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AERI\" target=\"_blank\">AERI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444733-evercore-likes-polarityte-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evercore likes PolarityTE in premarket analyst action</a></h4><ul><li>Aerie Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AERI' title='Aerie Pharmaceuticals, Inc.'>AERI</a>) initiated with Overweight rating and $80 (74% upside) price target at Piper Jaffray.</li><li>PolarityTE (NASDAQ:<a href='https://seekingalpha.com/symbol/PTE' title='PolarityTE, Inc.'>PTE</a>) initiated with Outperform rating and $26 (117% upside) price target at Evercore ISI. Shares up <font color=\"green\">9% </font>premarket.</li><li>Diplomat Pharmacy (NYSE:<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy, Inc.'>DPLO</a>) upgraded to Outperform with an $8 (37% upside) price target at Raymond James.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444733\" data-linked=\"Evercore likes PolarityTE in premarket analyst action\" data-tweet=\"$AERI $PTE $DPLO - Evercore likes PolarityTE in premarket analyst action https://seekingalpha.com/news/3444733-evercore-likes-polarityte-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3444733-evercore-likes-polarityte-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444728\" data-ts=\"1553166864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444728-biogen-and-eisai-bail-on-aducanumab-in-alzheimers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen and Eisai bail on aducanumab in Alzheimer&#39;s</a></h4><ul><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) and development partner Eisai (<a href='https://seekingalpha.com/symbol/ESALY' title='Eisai Co., Ltd.'>OTCPK:ESALY</a>) have decided to <a href=\"https://seekingalpha.com/pr/17451129-biogen-eisai-discontinue-phase-3-engage-emerge-trials-aducanumab-alzheimer-s-disease\" target=\"_blank\">terminate</a> two late-stage studies, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02477800?titles=engage&amp;lead=biogen&amp;rank=1\" target=\"_blank\">ENGAGE </a>and <a href=\"https://clinicaltrials.gov/ct2/show/NCT02484547?titles=emerge&amp;lead=biogen&amp;rank=1\" target=\"_blank\">EMERGE</a>, evaluating aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia.</li><li>The companies decided to pull the plug after a futility analysis showed that the studies were unlikely to meet the primary endpoints.</li><li>Certain sell-side analysts were predicting that aducanumab would be a big winner for BIIB.</li><li>The data will be submitted for presentation at future medical conferences.</li><li>BIIB, current halted, will resume trading at 7:30 am ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3444728\" data-linked=\"Biogen and Eisai bail on aducanumab in Alzheimer&#39;s\" data-tweet=\"$BIIB $ESALY $ESALF - Biogen and Eisai bail on aducanumab in Alzheimer&#39;s https://seekingalpha.com/news/3444728-biogen-and-eisai-bail-on-aducanumab-in-alzheimers?source=tweet\" data-url=\"https://seekingalpha.com/news/3444728-biogen-and-eisai-bail-on-aducanumab-in-alzheimers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3444708\" data-ts=\"1553165073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTL\" target=\"_blank\">MTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3444708-mechel-pao-reports-fy-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mechel PAO reports FY results</a></h4><ul><li>Mechel PAO (NYSE:<a href='https://seekingalpha.com/symbol/MTL' title='Mechel PAO'>MTL</a>): FY GAAP EPS of RUB30.34.</li><li>Revenue of RUB312.57B (+4.5% Y/Y)</li><li>Shares <font color=\"green\">+2.3%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17451068-mechel-reports-fy2018-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3444708\" data-linked=\"Mechel PAO reports FY results\" data-tweet=\"$MTL - Mechel PAO reports FY results https://seekingalpha.com/news/3444708-mechel-pao-reports-fy-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3444708-mechel-pao-reports-fy-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:44 AM </div></div></li>","count":68,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}